WO2005044793A2 - Nitrogen-containing fused heterocyclic compounds - Google Patents
Nitrogen-containing fused heterocyclic compounds Download PDFInfo
- Publication number
- WO2005044793A2 WO2005044793A2 PCT/US2004/035648 US2004035648W WO2005044793A2 WO 2005044793 A2 WO2005044793 A2 WO 2005044793A2 US 2004035648 W US2004035648 W US 2004035648W WO 2005044793 A2 WO2005044793 A2 WO 2005044793A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- compound
- mmol
- salt
- reaction
- Prior art date
Links
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 407
- 150000003839 salts Chemical class 0.000 claims abstract description 140
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 67
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 36
- 125000003277 amino group Chemical group 0.000 claims abstract description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 25
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 23
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000011593 sulfur Substances 0.000 claims abstract description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 16
- 239000001301 oxygen Substances 0.000 claims abstract description 16
- 229940002612 prodrug Drugs 0.000 claims abstract description 8
- 239000000651 prodrug Substances 0.000 claims abstract description 8
- -1 1- piperazinyl Chemical group 0.000 claims description 337
- 238000000034 method Methods 0.000 claims description 72
- 239000001257 hydrogen Substances 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000002252 acyl group Chemical group 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 150000002431 hydrogen Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 208000019901 Anxiety disease Diseases 0.000 claims description 12
- 230000036506 anxiety Effects 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 208000017194 Affective disease Diseases 0.000 claims description 6
- 208000019022 Mood disease Diseases 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 4
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 288
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 213
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 179
- 239000000203 mixture Substances 0.000 description 150
- 238000006243 chemical reaction Methods 0.000 description 139
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 109
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 107
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 93
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 92
- 235000019439 ethyl acetate Nutrition 0.000 description 91
- 239000002904 solvent Substances 0.000 description 89
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 88
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- 239000000243 solution Substances 0.000 description 75
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 72
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 69
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 64
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 58
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 52
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- 238000004587 chromatography analysis Methods 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 239000007787 solid Substances 0.000 description 47
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 44
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 43
- 102100021752 Corticoliberin Human genes 0.000 description 42
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 42
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 41
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 38
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 37
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 36
- 238000003818 flash chromatography Methods 0.000 description 35
- 230000002829 reductive effect Effects 0.000 description 35
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 33
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 32
- 235000019341 magnesium sulphate Nutrition 0.000 description 32
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- 239000012267 brine Substances 0.000 description 31
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 30
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 30
- 229960000583 acetic acid Drugs 0.000 description 30
- 239000000284 extract Substances 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- 230000035484 reaction time Effects 0.000 description 29
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 28
- 239000002585 base Substances 0.000 description 28
- 150000002148 esters Chemical class 0.000 description 28
- 238000001953 recrystallisation Methods 0.000 description 27
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 27
- 150000001408 amides Chemical class 0.000 description 26
- 238000000605 extraction Methods 0.000 description 26
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 25
- 238000002425 crystallisation Methods 0.000 description 25
- 230000008025 crystallization Effects 0.000 description 25
- 238000004090 dissolution Methods 0.000 description 25
- 150000002170 ethers Chemical class 0.000 description 25
- 229940052303 ethers for general anesthesia Drugs 0.000 description 25
- 229910052751 metal Inorganic materials 0.000 description 25
- 239000002184 metal Substances 0.000 description 25
- 238000002156 mixing Methods 0.000 description 25
- 238000012546 transfer Methods 0.000 description 25
- 239000002253 acid Substances 0.000 description 24
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 23
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 23
- 238000001914 filtration Methods 0.000 description 23
- 150000002825 nitriles Chemical class 0.000 description 23
- 239000008096 xylene Substances 0.000 description 23
- 239000003054 catalyst Substances 0.000 description 22
- 229920006395 saturated elastomer Polymers 0.000 description 22
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 21
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 21
- 229910052794 bromium Inorganic materials 0.000 description 21
- 150000008282 halocarbons Chemical class 0.000 description 21
- 231100000989 no adverse effect Toxicity 0.000 description 21
- 150000003462 sulfoxides Chemical class 0.000 description 21
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 20
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 20
- 150000001298 alcohols Chemical class 0.000 description 19
- 239000000843 powder Substances 0.000 description 19
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- 235000011181 potassium carbonates Nutrition 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 150000001412 amines Chemical class 0.000 description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- 235000017557 sodium bicarbonate Nutrition 0.000 description 16
- 235000011121 sodium hydroxide Nutrition 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 235000011054 acetic acid Nutrition 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 239000012362 glacial acetic acid Substances 0.000 description 15
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 229910000029 sodium carbonate Inorganic materials 0.000 description 15
- 235000017550 sodium carbonate Nutrition 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 14
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 13
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- 230000026030 halogenation Effects 0.000 description 12
- 238000005658 halogenation reaction Methods 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 235000011118 potassium hydroxide Nutrition 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 11
- 229910052763 palladium Inorganic materials 0.000 description 11
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 229910052987 metal hydride Inorganic materials 0.000 description 10
- 150000004681 metal hydrides Chemical class 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 10
- 235000015497 potassium bicarbonate Nutrition 0.000 description 10
- 239000011736 potassium bicarbonate Substances 0.000 description 10
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 10
- 229910000105 potassium hydride Inorganic materials 0.000 description 10
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 10
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 10
- 229910052783 alkali metal Inorganic materials 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000032050 esterification Effects 0.000 description 9
- 238000005886 esterification reaction Methods 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 229910000000 metal hydroxide Inorganic materials 0.000 description 9
- 150000004692 metal hydroxides Chemical class 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 9
- HQULYFAKUZDRPB-UHFFFAOYSA-N 6-bromo-2-[4-(trifluoromethoxy)phenoxy]-1,3-benzothiazole Chemical compound BrC1=CC2=C(N=C(S2)OC2=CC=C(C=C2)OC(F)(F)F)C=C1 HQULYFAKUZDRPB-UHFFFAOYSA-N 0.000 description 8
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 8
- 102400000739 Corticotropin Human genes 0.000 description 8
- 101800000414 Corticotropin Proteins 0.000 description 8
- 150000004703 alkoxides Chemical class 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 8
- 229960000258 corticotropin Drugs 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 150000007522 mineralic acids Chemical class 0.000 description 8
- 150000007524 organic acids Chemical class 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 7
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 239000002841 Lewis acid Substances 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 206010029216 Nervousness Diseases 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000002723 alicyclic group Chemical group 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 6
- 108010050742 corticotropin releasing hormone (9-41) Proteins 0.000 description 6
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 150000007517 lewis acids Chemical class 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- 230000002263 peptidergic effect Effects 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- MMSLSKDMIZOHRX-WYDAWZGFSA-N α-helical crf(9-41) Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(N)=O MMSLSKDMIZOHRX-WYDAWZGFSA-N 0.000 description 6
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical compound CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 229940013688 formic acid Drugs 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 210000003016 hypothalamus Anatomy 0.000 description 5
- 150000002466 imines Chemical class 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 5
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- KKYMYPLVBCVDPL-UHFFFAOYSA-N 2-isothiocyanato-1,3,5-trimethylbenzene Chemical compound CC1=CC(C)=C(N=C=S)C(C)=C1 KKYMYPLVBCVDPL-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000012954 diazonium Substances 0.000 description 4
- 150000001989 diazonium salts Chemical class 0.000 description 4
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 4
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 4
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 4
- 210000003635 pituitary gland Anatomy 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 3
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 3
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000007333 cyanation reaction Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 229940095574 propionic acid Drugs 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 3
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- HQEMUQNZGCZHHN-UHFFFAOYSA-N (3-nitrophenyl)thiourea Chemical compound NC(=S)NC1=CC=CC([N+]([O-])=O)=C1 HQEMUQNZGCZHHN-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 2
- DTSADOQCTSFGGH-UHFFFAOYSA-N 1-(4-methyl-3-nitrophenyl)-3-(2,4,6-trimethylphenyl)thiourea Chemical compound CC1=CC(C)=CC(C)=C1NC(=S)NC1=CC=C(C)C([N+]([O-])=O)=C1 DTSADOQCTSFGGH-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- XPMKBGRHYQWRJC-UHFFFAOYSA-N 1-[3-(hydroxymethyl)phenyl]-3-(2,4,6-trimethylphenyl)thiourea Chemical compound CC1=CC(C)=CC(C)=C1NC(=S)NC1=CC=CC(CO)=C1 XPMKBGRHYQWRJC-UHFFFAOYSA-N 0.000 description 2
- VYGUFGHAQHPCCC-UHFFFAOYSA-N 1-[3-amino-5-fluoro-2-(methylamino)phenyl]-3-(2,4,6-trimethylphenyl)thiourea Chemical compound CNC1=C(N)C=C(F)C=C1NC(=S)NC1=C(C)C=C(C)C=C1C VYGUFGHAQHPCCC-UHFFFAOYSA-N 0.000 description 2
- DBZZUAMZZYEIOR-UHFFFAOYSA-N 1-[5-(dipropylamino)-2-methylphenyl]-3-(2,4,6-trimethylphenyl)thiourea Chemical compound CCCN(CCC)C1=CC=C(C)C(NC(=S)NC=2C(=CC(C)=CC=2C)C)=C1 DBZZUAMZZYEIOR-UHFFFAOYSA-N 0.000 description 2
- QYYQTLLGVAPKPN-UHFFFAOYSA-N 1-ethylcyclopentene Chemical compound CCC1=CCCC1 QYYQTLLGVAPKPN-UHFFFAOYSA-N 0.000 description 2
- OEZXLKSZOAWNJU-UHFFFAOYSA-N 1-isothiocyanato-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(N=C=S)=C1 OEZXLKSZOAWNJU-UHFFFAOYSA-N 0.000 description 2
- CZZZABOKJQXEBO-UHFFFAOYSA-N 2,4-dimethylaniline Chemical compound CC1=CC=C(N)C(C)=C1 CZZZABOKJQXEBO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- AACMNEWXGKOJJK-UHFFFAOYSA-N 2-amino-6-nitrophenol Chemical compound NC1=CC=CC([N+]([O-])=O)=C1O AACMNEWXGKOJJK-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- JLGYEKNBUPNVAK-UHFFFAOYSA-N 2-n-methylbenzene-1,2,3-triamine Chemical compound CNC1=C(N)C=CC=C1N JLGYEKNBUPNVAK-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- IGIJSFNBEUBMGB-UHFFFAOYSA-N 4-(cyclohexyliminomethylideneamino)-n,n-diethylcyclohexan-1-amine Chemical compound C1CC(N(CC)CC)CCC1N=C=NC1CCCCC1 IGIJSFNBEUBMGB-UHFFFAOYSA-N 0.000 description 2
- GDIIPKWHAQGCJF-UHFFFAOYSA-N 4-Amino-2-nitrotoluene Chemical compound CC1=CC=C(N)C=C1[N+]([O-])=O GDIIPKWHAQGCJF-UHFFFAOYSA-N 0.000 description 2
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 2
- QQYYVGPPWZJSGZ-UHFFFAOYSA-N 4-fluoro-n-methyl-2,6-dinitroaniline Chemical compound CNC1=C([N+]([O-])=O)C=C(F)C=C1[N+]([O-])=O QQYYVGPPWZJSGZ-UHFFFAOYSA-N 0.000 description 2
- USIRHWNHZJWHQH-UHFFFAOYSA-N 4-isothiocyanato-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(N=C=S)C=C1[N+]([O-])=O USIRHWNHZJWHQH-UHFFFAOYSA-N 0.000 description 2
- 125000005814 5,6-dihydro-2-naphthyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])C2=C([H])C([H])=C(*)C([H])=C12 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- PDURYSFELRUNPS-UHFFFAOYSA-N 7-(bromomethyl)-n-(2,4,6-trimethylphenyl)-1,3-benzothiazol-2-amine Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC2=CC=CC(CBr)=C2S1 PDURYSFELRUNPS-UHFFFAOYSA-N 0.000 description 2
- XRALEOCPURMVJK-UHFFFAOYSA-N 7-[(dipropylamino)methyl]-n-(2,4,6-trimethylphenyl)-1,3-benzothiazol-2-amine Chemical compound S1C=2C(CN(CCC)CCC)=CC=CC=2N=C1NC1=C(C)C=C(C)C=C1C XRALEOCPURMVJK-UHFFFAOYSA-N 0.000 description 2
- QSFYHTYXQAKFFR-UHFFFAOYSA-N 7-bromo-2-chloro-3-methyl-n,n-dipropylbenzimidazol-4-amine Chemical compound CCCN(CCC)C1=CC=C(Br)C2=C1N(C)C(Cl)=N2 QSFYHTYXQAKFFR-UHFFFAOYSA-N 0.000 description 2
- PNGLBZFAYSCFFJ-UHFFFAOYSA-N 7-nitro-n-(1-phenylethyl)-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC([N+]([O-])=O)=C2SC=1NC(C)C1=CC=CC=C1 PNGLBZFAYSCFFJ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 description 2
- 238000005361 D2 NMR spectroscopy Methods 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000878664 Homo sapiens Corticotropin-releasing factor receptor 2 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- 229910020889 NaBH3 Inorganic materials 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000000297 Sandmeyer reaction Methods 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- VBESKIAEWORCCZ-UHFFFAOYSA-N [2-(2,4,6-trimethylanilino)-1,3-benzothiazol-7-yl]methanol Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC2=CC=CC(CO)=C2S1 VBESKIAEWORCCZ-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- PQLAYKMGZDUDLQ-UHFFFAOYSA-K aluminium bromide Chemical compound Br[Al](Br)Br PQLAYKMGZDUDLQ-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000049 anti-anxiety effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 125000006251 butylcarbonyl group Chemical group 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- XSNBOUDHWWROII-UHFFFAOYSA-N imidazo[1,2-a]pyridin-5-amine Chemical compound NC1=CC=CC2=NC=CN12 XSNBOUDHWWROII-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960002523 mercuric chloride Drugs 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910001507 metal halide Inorganic materials 0.000 description 2
- 150000005309 metal halides Chemical class 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- UHAAFJWANJYDIS-UHFFFAOYSA-N n,n'-diethylmethanediimine Chemical compound CCN=C=NCC UHAAFJWANJYDIS-UHFFFAOYSA-N 0.000 description 2
- OZQGGFOWOQBLCC-UHFFFAOYSA-N n-[7-(dipropylamino)-1,3-benzothiazol-2-yl]-2,4,6-trimethylbenzamide Chemical compound S1C=2C(N(CCC)CCC)=CC=CC=2N=C1NC(=O)C1=C(C)C=C(C)C=C1C OZQGGFOWOQBLCC-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HEFPRZMHFIFYEX-UHFFFAOYSA-N n-butyl-2-chloro-n-(2-methoxyphenyl)-3-methylbenzimidazol-4-amine Chemical compound C=1C=CC=2N=C(Cl)N(C)C=2C=1N(CCCC)C1=CC=CC=C1OC HEFPRZMHFIFYEX-UHFFFAOYSA-N 0.000 description 2
- YEYQXUWULBDKHV-UHFFFAOYSA-N n-methyl-2,6-dinitroaniline Chemical compound CNC1=C([N+]([O-])=O)C=CC=C1[N+]([O-])=O YEYQXUWULBDKHV-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- KPADFPAILITQBG-UHFFFAOYSA-N non-4-ene Chemical compound CCCCC=CCCC KPADFPAILITQBG-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001451 organic peroxides Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- HBEQXAKJSGXAIQ-UHFFFAOYSA-N oxopalladium Chemical compound [Pd]=O HBEQXAKJSGXAIQ-UHFFFAOYSA-N 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910003445 palladium oxide Inorganic materials 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- MIROPXUFDXCYLG-UHFFFAOYSA-N pyridine-2,5-diamine Chemical compound NC1=CC=C(N)N=C1 MIROPXUFDXCYLG-UHFFFAOYSA-N 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- MFDVNDHZZOHMGF-UHFFFAOYSA-N (2,4-dimethylphenyl)-[5-(dipropylamino)imidazo[1,2-a]pyridin-2-yl]methanone Chemical compound C=1N2C(N(CCC)CCC)=CC=CC2=NC=1C(=O)C1=CC=C(C)C=C1C MFDVNDHZZOHMGF-UHFFFAOYSA-N 0.000 description 1
- TYONHSPZXLFWKI-UHFFFAOYSA-N (2,4-dimethylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(C)=C1 TYONHSPZXLFWKI-UHFFFAOYSA-N 0.000 description 1
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OJZQOQNSUZLSMV-UHFFFAOYSA-N (3-aminophenyl)methanol Chemical compound NC1=CC=CC(CO)=C1 OJZQOQNSUZLSMV-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- VGRXAHXMIDCTNV-UHFFFAOYSA-N (6-chlorobenzotriazol-1-yl) 4-chlorobenzenesulfonate Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)ON1C2=CC(Cl)=CC=C2N=N1 VGRXAHXMIDCTNV-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- FKZYYYDRLJCHGL-UHFFFAOYSA-N 1,1,3-trimethoxypropane Chemical compound COCCC(OC)OC FKZYYYDRLJCHGL-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- YZLSXKIVGNQGPR-UHFFFAOYSA-N 1,2-oxazole;hydrate Chemical compound O.C=1C=NOC=1 YZLSXKIVGNQGPR-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- MASDFXZJIDNRTR-UHFFFAOYSA-N 1,3-bis(trimethylsilyl)urea Chemical compound C[Si](C)(C)NC(=O)N[Si](C)(C)C MASDFXZJIDNRTR-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- CKZBRKLFMRHHMA-UHFFFAOYSA-N 1,3-dimethoxy-2-phenylbenzene Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1 CKZBRKLFMRHHMA-UHFFFAOYSA-N 0.000 description 1
- VDHAOOWNWXMEJD-UHFFFAOYSA-N 1-(2-hydroxy-3-nitrophenyl)-3-(2,4,6-trimethylphenyl)thiourea Chemical compound CC1=CC(C)=CC(C)=C1NC(=S)NC1=CC=CC([N+]([O-])=O)=C1O VDHAOOWNWXMEJD-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- ZRCPIQRUXCRUKJ-UHFFFAOYSA-N 1-[3-amino-2-(methylamino)phenyl]-3-(2,4,6-trimethylphenyl)thiourea Chemical compound CNC1=C(N)C=CC=C1NC(=S)NC1=C(C)C=C(C)C=C1C ZRCPIQRUXCRUKJ-UHFFFAOYSA-N 0.000 description 1
- XKLCOVZMZKNSSH-UHFFFAOYSA-N 1-[4-(dipropylamino)pyridin-2-yl]-3-(2,4,6-trimethylphenyl)thiourea Chemical compound CCCN(CCC)C1=CC=NC(NC(=S)NC=2C(=CC(C)=CC=2C)C)=C1 XKLCOVZMZKNSSH-UHFFFAOYSA-N 0.000 description 1
- KJUUJHJQXWLTOT-UHFFFAOYSA-N 1-amino-4-benzyl-3-methyl-7-propylbenzimidazol-2-one Chemical compound C(C1=CC=CC=C1)C1=CC=C(C2=C1N(C(N2N)=O)C)CCC KJUUJHJQXWLTOT-UHFFFAOYSA-N 0.000 description 1
- FJLFSYRGFJDJMQ-UHFFFAOYSA-N 1-bromo-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1 FJLFSYRGFJDJMQ-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- UKRQMDIFLKHCRO-UHFFFAOYSA-N 2,4,6-trimethylbenzoyl chloride Chemical compound CC1=CC(C)=C(C(Cl)=O)C(C)=C1 UKRQMDIFLKHCRO-UHFFFAOYSA-N 0.000 description 1
- JUOGRBULLOEKKQ-UHFFFAOYSA-N 2,4-dimethylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C(C)=C1 JUOGRBULLOEKKQ-UHFFFAOYSA-N 0.000 description 1
- KUFFULVDNCHOFZ-UHFFFAOYSA-N 2,4-xylenol Chemical compound CC1=CC=C(O)C(C)=C1 KUFFULVDNCHOFZ-UHFFFAOYSA-N 0.000 description 1
- JCRIDWXIBSEOEG-UHFFFAOYSA-N 2,6-dinitrophenol Chemical compound OC1=C([N+]([O-])=O)C=CC=C1[N+]([O-])=O JCRIDWXIBSEOEG-UHFFFAOYSA-N 0.000 description 1
- WTRLCCNVDIASDH-UHFFFAOYSA-N 2-(1-phenylethyl)-3H-1,3-benzothiazole-2,7-diamine Chemical compound C1(=CC=CC=C1)C(C)C1(SC2=C(N1)C=CC=C2N)N WTRLCCNVDIASDH-UHFFFAOYSA-N 0.000 description 1
- DYMIUPOMRZSREP-UHFFFAOYSA-N 2-(2,4-dimethylphenoxy)-1,3-benzothiazol-7-amine Chemical compound CC1=CC(C)=CC=C1OC1=NC2=CC=CC(N)=C2S1 DYMIUPOMRZSREP-UHFFFAOYSA-N 0.000 description 1
- OIPLCMWKGKOBMF-UHFFFAOYSA-N 2-(2,4-dimethylphenyl)-1-[5-(dipropylamino)imidazo[1,2-a]pyridin-2-yl]ethanone Chemical compound CC1=C(C=CC(=C1)C)CC(=O)C=1N=C2N(C(=CC=C2)N(CCC)CCC)C=1 OIPLCMWKGKOBMF-UHFFFAOYSA-N 0.000 description 1
- BFJRUGZCRDQKTP-UHFFFAOYSA-N 2-(4-bromo-2-methoxy-6-methylphenyl)-3-methyl-1H-benzimidazole-2,4-diamine Chemical compound BrC1=CC(=C(C(=C1)C)C1(NC2=C(N1C)C(=CC=C2)N)N)OC BFJRUGZCRDQKTP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- PVRGKJWOLCJJAN-UHFFFAOYSA-N 2-bromo-n,n-dipropylimidazo[1,2-a]pyridin-5-amine Chemical compound CCCN(CCC)C1=CC=CC2=NC(Br)=CN12 PVRGKJWOLCJJAN-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- JSXJYGLDJJHAPT-UHFFFAOYSA-N 2-chloro-5-fluoro-1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC([N+]([O-])=O)=C1Cl JSXJYGLDJJHAPT-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- AVZBOAGCVKEESJ-UHFFFAOYSA-O 2-ethyl-1,2-benzoxazol-2-ium-7-ol Chemical class C1=CC(O)=C2O[N+](CC)=CC2=C1 AVZBOAGCVKEESJ-UHFFFAOYSA-O 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 description 1
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- KJAYIENMJJRIDU-UHFFFAOYSA-N 2-n-(1-phenylethyl)-1,3-benzothiazole-2,7-diamine Chemical compound N=1C2=CC=CC(N)=C2SC=1NC(C)C1=CC=CC=C1 KJAYIENMJJRIDU-UHFFFAOYSA-N 0.000 description 1
- XXQLTGWHMPKIPD-UHFFFAOYSA-N 2-n-(2,4,6-trimethylphenyl)-1,3-benzothiazole-2,7-diamine Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC2=CC=CC(N)=C2S1 XXQLTGWHMPKIPD-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 description 1
- VLODOLKTCMEMIT-UHFFFAOYSA-N 3-[[tert-butyl(dimethyl)silyl]oxymethyl]aniline Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(N)=C1 VLODOLKTCMEMIT-UHFFFAOYSA-N 0.000 description 1
- PKLPQOJFHFGVBS-UHFFFAOYSA-N 3-acetyl-4-hydroxy-6-methyl-2h-pyran-2-one Chemical compound CC(=O)C1=C(O)C=C(C)OC1=O PKLPQOJFHFGVBS-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- IFJOCLPJVGWHTI-UHFFFAOYSA-N 3-methyl-2-n-(2,4,6-trimethylphenyl)benzimidazole-2,4-diamine Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC2=CC=CC(N)=C2N1C IFJOCLPJVGWHTI-UHFFFAOYSA-N 0.000 description 1
- IQNALKANRMLSSH-UHFFFAOYSA-N 3-methyl-4-N,4-N-dipropyl-2-(2,4,6-trimethylphenyl)-1H-benzimidazole-2,4-diamine Chemical compound C1(=C(C(=CC(=C1)C)C)C1(NC2=C(N1C)C(=CC=C2)N(CCC)CCC)N)C IQNALKANRMLSSH-UHFFFAOYSA-N 0.000 description 1
- PFTCNCLYRQAXNC-UHFFFAOYSA-N 3-methyl-4-n-propyl-2-n-(2,4,6-trimethylphenyl)benzimidazole-2,4-diamine Chemical compound CN1C=2C(NCCC)=CC=CC=2N=C1NC1=C(C)C=C(C)C=C1C PFTCNCLYRQAXNC-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ROSWOLRBXXNBKJ-UHFFFAOYSA-N 4-(7-nitro-1,3-benzothiazol-2-yl)morpholine Chemical compound S1C=2C([N+](=O)[O-])=CC=CC=2N=C1N1CCOCC1 ROSWOLRBXXNBKJ-UHFFFAOYSA-N 0.000 description 1
- BLBDTBCGPHPIJK-UHFFFAOYSA-N 4-Amino-2-chloropyridine Chemical compound NC1=CC=NC(Cl)=C1 BLBDTBCGPHPIJK-UHFFFAOYSA-N 0.000 description 1
- HURLDMSOLJJDGK-UHFFFAOYSA-N 4-amino-3-methyl-1h-benzimidazol-2-one Chemical compound C1=CC=C2NC(=O)N(C)C2=C1N HURLDMSOLJJDGK-UHFFFAOYSA-N 0.000 description 1
- MTRIPTAVYRAWRG-UHFFFAOYSA-N 4-bromo-2-methoxy-6-methylaniline Chemical compound COC1=CC(Br)=CC(C)=C1N MTRIPTAVYRAWRG-UHFFFAOYSA-N 0.000 description 1
- SQTLUXJWUCHKMT-UHFFFAOYSA-N 4-bromo-n,n-diphenylaniline Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SQTLUXJWUCHKMT-UHFFFAOYSA-N 0.000 description 1
- PSEHUZQOXDGFGD-UHFFFAOYSA-N 4-chloro-2-methoxy-6-methylaniline Chemical compound COC1=CC(Cl)=CC(C)=C1N PSEHUZQOXDGFGD-UHFFFAOYSA-N 0.000 description 1
- MDOWEUXXLVBZIU-UHFFFAOYSA-N 4-fluoro-2,6-dinitrophenol Chemical compound OC1=C([N+]([O-])=O)C=C(F)C=C1[N+]([O-])=O MDOWEUXXLVBZIU-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- MNVMYTVDDOXZLS-UHFFFAOYSA-N 4-methoxyguaiacol Natural products COC1=CC=C(O)C(OC)=C1 MNVMYTVDDOXZLS-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- NXRUAZQUKNPSEF-UHFFFAOYSA-N 4-methyl-3-nitro-n,n-dipropylaniline Chemical compound CCCN(CCC)C1=CC=C(C)C([N+]([O-])=O)=C1 NXRUAZQUKNPSEF-UHFFFAOYSA-N 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OLQSQQDUVJQGLP-UHFFFAOYSA-N 4-n-butyl-4-n-(4-methoxyphenyl)-3-methyl-2-n-(2,4,6-trimethylphenyl)benzimidazole-2,4-diamine Chemical compound C=1C=CC=2N=C(NC=3C(=CC(C)=CC=3C)C)N(C)C=2C=1N(CCCC)C1=CC=C(OC)C=C1 OLQSQQDUVJQGLP-UHFFFAOYSA-N 0.000 description 1
- 125000005812 5,6-dihydro-1-naphthyl group Chemical group [H]C1=C([H])C(*)=C2C([H])=C([H])C([H])([H])C([H])([H])C2=C1[H] 0.000 description 1
- RGMKVCGLKXICTH-UHFFFAOYSA-N 5-(chloromethyl)-7-nitro-n-(2,4,6-trimethylphenyl)-1,3-benzothiazol-2-amine Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC2=CC(CCl)=CC([N+]([O-])=O)=C2S1 RGMKVCGLKXICTH-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- XAYAJDPTGRJHGG-UHFFFAOYSA-N 5-nitro-n,n-dipropyl-2-(2,4,6-trimethylanilino)-1,3-benzothiazole-7-carboxamide Chemical compound S1C=2C(C(=O)N(CCC)CCC)=CC([N+]([O-])=O)=CC=2N=C1NC1=C(C)C=C(C)C=C1C XAYAJDPTGRJHGG-UHFFFAOYSA-N 0.000 description 1
- QJRIYKUMRXSAQZ-UHFFFAOYSA-N 6-fluoro-3-methyl-4-n,4-n-dipropyl-2-n-(2,4,6-trimethylphenyl)benzimidazole-2,4-diamine Chemical compound CN1C=2C(N(CCC)CCC)=CC(F)=CC=2N=C1NC1=C(C)C=C(C)C=C1C QJRIYKUMRXSAQZ-UHFFFAOYSA-N 0.000 description 1
- SMGFFVNMFGDKHD-UHFFFAOYSA-N 7-n,7-n-dipropyl-2-n-(2,4,6-trimethylphenyl)-[1,3]thiazolo[4,5-b]pyridine-2,7-diamine Chemical compound S1C=2C(N(CCC)CCC)=CC=NC=2N=C1NC1=C(C)C=C(C)C=C1C SMGFFVNMFGDKHD-UHFFFAOYSA-N 0.000 description 1
- CDSPRWKEULQFED-UHFFFAOYSA-N 7-nitro-n-(2,4,6-trimethylphenyl)-1,3-benzothiazol-2-amine Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC2=CC=CC([N+]([O-])=O)=C2S1 CDSPRWKEULQFED-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 108091005470 CRHR2 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 101000948733 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Probable phospholipid translocase non-catalytic subunit CRF1 Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- JXYRIQRQKAUQIY-UHFFFAOYSA-N acetic acid;oxolane Chemical compound CC(O)=O.C1CCOC1 JXYRIQRQKAUQIY-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000316 alkaline earth metal phosphate Inorganic materials 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001398 aluminium Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 150000001845 chromium compounds Chemical class 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 125000001485 cycloalkadienyl group Chemical group 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000005993 intestine dysfunction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- VXDVAWSWYRSEMS-UHFFFAOYSA-N methyl 3-nitro-5-[(2,4,6-trimethylphenyl)carbamothioylamino]benzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC(NC(=S)NC=2C(=CC(C)=CC=2C)C)=C1 VXDVAWSWYRSEMS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical class C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- NXDKPPOLEGDUHN-UHFFFAOYSA-N n-(7-amino-1,3-benzothiazol-2-yl)-2,4,6-trimethylbenzamide Chemical compound CC1=CC(C)=CC(C)=C1C(=O)NC1=NC2=CC=CC(N)=C2S1 NXDKPPOLEGDUHN-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- JVHPKYBRJQNPAT-UHFFFAOYSA-N n-cyclohexyl-2,2-diphenylethenimine Chemical compound C1CCCCC1N=C=C(C=1C=CC=CC=1)C1=CC=CC=C1 JVHPKYBRJQNPAT-UHFFFAOYSA-N 0.000 description 1
- LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical compound CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 description 1
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- NLEUXPOVZGDKJI-UHFFFAOYSA-N nickel(2+);dicyanide Chemical compound [Ni+2].N#[C-].N#[C-] NLEUXPOVZGDKJI-UHFFFAOYSA-N 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- PBDBXAQKXCXZCJ-UHFFFAOYSA-L palladium(2+);2,2,2-trifluoroacetate Chemical compound [Pd+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F PBDBXAQKXCXZCJ-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004932 phenoxathinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- VHNQIURBCCNWDN-UHFFFAOYSA-N pyridine-2,6-diamine Chemical compound NC1=CC=CC(N)=N1 VHNQIURBCCNWDN-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002186 septum of brain Anatomy 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- VFWRGKJLLYDFBY-UHFFFAOYSA-N silver;hydrate Chemical compound O.[Ag].[Ag] VFWRGKJLLYDFBY-UHFFFAOYSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940048181 sodium sulfide nonahydrate Drugs 0.000 description 1
- WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 150000003608 titanium Chemical class 0.000 description 1
- UBZYKBZMAMTNKW-UHFFFAOYSA-J titanium tetrabromide Chemical compound Br[Ti](Br)(Br)Br UBZYKBZMAMTNKW-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to novel nitrogen- containing fused heterocyclic ⁇ compounds having CRF (corticotropin releasing factor) antagonistic activity and pharmaceutical compositions containing them.
- CRF corticotropin releasing factor
- Corticotropin-releasing factor (hereinafter, abbreviated as "CRF”) is a neuropeptide composed of 41 amino acids, and was isolated and purified as a peptide promoting release of adrenocorticotropic hormone (ACTH) from pituitary gland.
- ACTH adrenocorticotropic hormone
- CRF is synthesized as a carboxy-terminal of prepro CRF, cut and secreted.
- the CRF peptide and a mRNA thereof are present at the largest amount in hypothalamus and pituitary gland, and are widely distributed in a brain such as cerebral cortex, cerebellum, hippocampus and corpus amygdaloideum.
- a CRF receptor is a 7- transmembrane G protein-coupled receptor, and two subtypes of CRFl and CRF2 are present. It is reported that CRF1 is present mainly in cerebral cortex, cerebellum, olfactory bulb, pituitary gland and tonsil nucleus.
- the CRF2 receptor has two subtypes of CRF2 and CRF2 ⁇ . It was made clear that the CRF2 ⁇ receptor is distributed much in hypothalamus, septal area and choroids plexus, and the CRF2 ⁇ receptor is present mainly in peripheral tissues such as skeletal muscle and is distributed in a blood vessel in a brain [J. Neurosci. 15, 6340(1995); Endocrinology, 137, 72(1996); Biochim. Biophys. Acta, 1352, 129(1997)]. Since each receptor differs in distribution in a living body, it is suggested that a role thereof is also different [Trends. Pharmacol. Sci. 23, 71(2002)].
- CRF As a physiological action of CRF, the action on the endocrine system is known in which CRF is produced and secreted in response to stress in hypothalamus and acts on pituitary gland to promote the release of ACTH [Recent Prog, Horm. Res., 39, 245(1983)].
- CRF acts as a neurotransmitter or a neuroregulating factor in a brain, and integrates electrophysiology, autonomic nerve and conducts to stress [Brain Res. Rev., 15, 71(1990); Pharmacol. Rev., 43, 425(1991)].
- ⁇ - helical CRF (9-41) of a peptidergic CRF receptor antagonist exerts an anti-anxiety action in an animal model [Brain Res., 509, 80(1990); J. Neurosci., 14, 2579(1994)].
- a blood pressure, a heart rate and a body temperature of a rat are increased by stress or CRF administration, but the ⁇ -helical CRF (9-41) of a peptidergic CRF antagonist inhibits the increase in a blood pressure, a heart rate and a body temperature due to stress [J. Physiol., 460, 221(1993)].
- the ⁇ -helical CRF(9-41) of a peptidergic CRF receptor antagonist inhibits abnormal conducts due to withdrawal of a dependent drug such as an alcohol and a cocaine [Psychopharmacology, 103, 227(1991); Pharmacol. Rev.53, 209(2001)].
- a dependent drug such as an alcohol and a cocaine
- learning and memory are promoted by CRF administration in a rat [Nature, 375, 284(1995); Neuroendocrinology, 57, 1071(1993); Eur. J. Pharmacol., 405, 225(2000)]. Since CRF is associated with stress response in a living body, there are clinical reports regarding stress- associated depression or anxiety.
- the CRF concentration in a cerebrospinal fluid of a depression patient is higher as compared with that of a normal person [Am. J. Psychiatry, 144, 873(1987)], and the mRNA level of CRF in hypothalamus of a depression patient is increased as compared with that of a normal person [Am. J. Psychiatry, 152, 1372(1995)].
- a CRF binding site of cerebral cortex of a patient who suicided by depression is decreased [Arch. Gen. Psychiatry, 45, 577(1988)].
- the increase in the plasma ACTH concentration due to CRF administration is small in a depression patient [N. Engl. J. Med., 314, 1329(1986)].
- CRF inhibits ingestion in an experimental animal such as a rat [Life Sci., 31, 363 (1982);
- ⁇ -helical CRF (9-41) of a peptidergic CRF antagonist inhibited decrease of ingestion due to stress loading in an experimental model [Brain Res. Bull., 17, 285(1986)].
- CRF inhibited weight gain in a hereditary obesity animal
- ⁇ -helical CRF (9-41) of a peptidergic CRF antagonist has a restoring action for hypofunction of stomach by abdominal operation [Am. J. Physiol., 258, G152(1990)].
- CRF inhibits secretion of a bicarbonate ion in stomach, decreases gastric acid secretion and inhibits ulcer due to cold restriction stress
- ⁇ -helical CRF (9-41) of a peptidergic CRF antagonist shows the inhibitory action on gastric acid secretion decrease, gastric excretion decrease, small intestinal transport decrease and large intestinal transport enhancement due to restriction stress [Gastroenterology, 95, 1510(1988)].
- CRF decreases a threshold of discomfort [Gastroenterology, 109, 1772(1995); Neurogastroenterol . Mot., 8, 9 [1996].
- CRF induces degranulation of a mast cell and enhances the blood vessel permeability [Endocrinology, 139, 403(1998); J.Pharmacol. Exp. Ther., 288, 1349(1999)]. CRF can be detected also in a thyroid gland of ' autoimmune thyroiditis- patient [Am. J. Pathol. 145, 1159(1994)]. When CRF is administered to an experimental autoimmune cerebrospinal meningitis rat, the progression of symptom such as paralysis was remarkably inhibited [J. Immunil., 158, 5751(1997)].
- the immune response activity such as T-lymphocyte proliferation and the natural killer cell activity is reduced by CRF administration or stress loading [Endocrinology, 128, 1329(1991)].
- CRF antagonistic compound would exert an excellent effect for treating or preventing various diseases in which CRF is involved.
- peptide CRF receptor antagonists are reported in which a part of an amino acid sequence of CRF or associated peptides of a human or other mammals is altered or deleted, and they are reported to show a pharmacological action such as ACTH release- inhibiting action and anti-anxiety action [Science, 224, 889(1984); J. Pharmacol. Exp.
- ring A is a 5-membered ring represented by the formula (A* ) : wherein X is a carbon and X 1 is an oxygen, a sulfur or - NR 5 - (wherein R 5 is a hydrogen, an optionally substituted hydrocarbyl or an acyl) , or formula (A"):
- X is a nitrogen and R ⁇ is a hydrogen, an optionally substituted hydrocarbyl or an acyl;
- R 1 is (1) an amino substituted by two substituents selected from an optionally substituted hydrocarbyl group and an optionally substituted heterocyclic group, or (2) an optionally substituted cyclic amino, provided that the amino nitrogen of said cyclic amino has no carbonyl adjacent to the nitrogen;
- R 2 is an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl or an optionally substituted heterocyclic;
- Y 1 , Y 2 and Y 3 are each an optionally substituted methyne or a nitrogen, provided that one or less of Y 1 , Y 2 and Y 3 is nitrogen;
- W is a bond, -(CH 2 )n- or -(CH 2 ) m -C0- (wherein n is an integer of 1 to 4 and m is an integer of 0 to 4) ; Z is a bond, -CO-, an oxygen, a sulfur, -SO-, -S0 2 -, -NR 4 -, -NR 4 -alk-, -CONR 4 - or -NR 4 CO- (wherein alk is an optionally substituted C 1 - 4 alkylene and R 4 is a hydrogen, an optionally substituted hydrocarbyl or an acyl) ; provided that (i) the compound wherein ring A is the 5- membered ring, of the formula A' (wherein X is a carbon and X 1 is a sulfur) , W is a bond, Z is -NHCO- or -CONH-, and Y 1 is CR 3a (wherein R 3a is a hydrogen, a halogen, or
- Y 1 is CR 3a
- Y 2 is CR 3b
- Y 3 is CR 3c
- R 3a , R 3b and R 3c are independently a hydrogen, a halogen, a nitro, an ' optionally substituted C 1 - 4 hydrocarbyl, an optionally substituted C 1 - 4 hydrocarbyloxy, an optionally substituted C 1 -. 4 hydrocarbylthio, an optionally substituted amino or an acyl containing up to 4 carbon atoms
- R 5a is a hydrogen, an optionally substituted C ⁇ _ 4 alkyl or an acyl containing up to 4 carbon atoms;
- Y 1 is CR 3a
- Y 2 is CR 3b
- Y 3 is CR 3c
- R 3a , R 3b and R 3c is independently a hydrogen, a halogen or an optionally substituted hydrocarbyl
- W is a bond
- R 2 is an optionally substituted phenyl or an optionally substituted 5- or 6-membered heterocyclic
- Z is -NR 4 - (wherein R 4 is a hydrogen or an optionally substituted hydrocarbyl) ;
- Y 1 is CR 3a
- Y 2 is CR 3b
- Y 3 is CR 3c (wherein R 3a , R 3b and R 3c are independently a hydrogen, a halogen
- ring A is a 5-membered ring represented by the formula (A' ) :
- X is a carbon and X 1 is an oxygen, a sulfur or - NR 5 - (wherein R 5 is a hydrogen, an optionally substituted hydrocarbyl or an acyl), or formula (A"):
- X is a nitrogen and R is a hydrogen, an optionally substituted hydrocarbyl or an acyl;
- R la is (1) an amino substituted by two substituents selected from an optionally substituted hydrocarbyl group and an optionally substituted heterocyclic group, or (2) an optionally substituted cyclic amino;
- R 2 is an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl or an optionally substituted heterocyclic;
- Y 1 , Y 2 and Y 3 are each an optionally substituted methyne. or a nitrogen, provided that one or less of Y 1 , Y 2 and Y 3 is nitrogen;
- W is a bond, -(CH 2 ) n - or -(CH 2 ) m -CO-, wherein n is an integer of 1 to 4 and m is an integer of 0 to 4; Z is a bond, -CO-, an oxygen, a sulfur, -SO-, -S0 2 -, -NR 4 -, -NR-alk-, -CONR 4 - or -NR 4 CO- (wherein alk is an optionally substituted C ⁇ - 4 alkylene and R 4 is a hydrogen, an optionally substituted hydrocarbyl or an acyl) ; provided that the compound wherein ring A is the 5-membered ring of the formula A' (wherein X is a carbon and X 1 is a sulfur) , W is a bond, Z is -NHCO- or -CONH-, and Y 1 is CR 3a (wherein R 3a is a halogen, or an alkoxy) is excluded; or a
- An agent for preventing or treating a disease wherein a CRF receptor is implicated which comprises the compound (la) according to the above-mentioned (15) or a salt thereof;
- An agent for preventing or treating affective disorder, depression or anxiety which comprises the compound (la) according to the above-mentioned (15) or a salt thereof.
- hydrocarbyl means a univalent group containing only carbon and hydrogen.
- ring A of the formulas (I) and (la) is a 5-membered ring represented by the following formula A' or A":
- X represents a carbon and X 1 represents an oxygen, a sulfur or -NR 5 - (wherein R 5 is a hydrogen or an optionally substituted hydrocarbyl or an acyl) .
- examples of the 5-membered ring of the formula (A') include an oxazole ring, a thiazole ring and an imidazole ring.
- examples of the "hydrocarbyl" of "an optionally substituted hydrocarbyl” represented by R 5 of the formula: -NR 5 - include an optionally substituted aliphatic hydrocarbon group, an optionally substituted alicyclic hydrocarbon group, an optionally substituted alicyclic- aliphatic hydrocarbon group, an optionally substituted aromatic hydrocarbon group, an optionally substituted aromatic-aliphatic hydrocarbon group (an aralkyl group) , and the like.
- aliphatic hydrocarbon group examples include a saturated aliphatic hydrocarbon group having 1-8 carbon atoms (e.g., alkyl group) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, heptyl, octyl, etc.; and an unsaturated aliphatic hydrocarbon group having 2-8 carbon atoms (e.g., alkenyl group, alkynyl group, alkadienyl group, alkadiynyl group, etc.) such as vinyl, allyl, 1-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl
- alicyclic hydrocarbon group examples include a saturated alicyclic hydrocarbon group having 3-7 carbon atoms (e.g., cycloalkyl group, etc.) such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like; an unsaturated alicyclic hydrocarbon group having 3-7 carbon atoms (e.g., cycloalkenyl group, cycloalkadienyl group, etc.) such as 1-cyclopentenyl, 2-cyclopentenyl, 3- cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3- cyclohexenyl, 1-cycloheptenyl, 2-cycloheptenyl, 3- cycloheptenyl, 2, 4-cycloheptadienyl, etc.; a partly saturated and fused bicyclic hydrocarbon group [preferably, Cg-io partly saturated and fused
- Said alicyclic hydrocarbon group may be cross-linked.
- said alicyclic-aliphatic hydrocarbon group include those where the above-mentioned alicyclic hydrocarbon group and the above-mentioned aliphatic hydrocarbon group are combined, for example, those having 4-14 carbon atoms such as cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, 2-cyclopentenylmethyl, 3- cyclopentenylmethyl, cyclopentylethyl, cyclohexylmethyl, 2- cyclohexenylmethyl, 3-cyclohexenylmethyl, cyclohexylethyl, cycloheptylmethyl, cycloheptylethyl, 2- (3, 4-dihydro-2- naphtyl) ethyl, 2- (1, 2, 3, 4-tetrahydro-2-naphtyl) e
- C 3 _ cycloalkyl- Ci_ 4 alkyl group e.g., C 3 _ 7 cycloalkenyl-C ⁇ - 4 alkyl group, C3_ 7 cycloalkyl-C 2 -4 alkenyl group, C 3 - cycloalkenyl-C 2 - 4 alkenyl group, Cg-io partly saturated and fused bicyclic hydrocarbon-Ci- 4 alkyl group, Cg-io partly saturated and fused bicyclic hydrocarbon-C 2 - 4 alkenyl groups, etc.).
- aromatic hydrocarbon group examples include an aryl group having 6-10 carbon atoms (including that where a 5- to 6-membered non-aromatic hydrocarbon ring is fused with phenyl group) such as phenyl, ⁇ -naphthyl, ⁇ -naphthyl, 4-indenyl, 5-indenyl, 4-indanyl, 5-indanyl, 5,6,7,8- tetrahydro-1-naphthyl, 5, 6, 7, 8-tetrahydro-2-naphthyl, 5, 6- dihydro-1-naphthyl, 5, 6-dihydro-2-naphthyl, 5, 6-dihydro-3- naphthyl, 5, 6-dihydro-4-naphthyl, etc.; and the like.
- aryl group having 6-10 carbon atoms including that where a 5- to 6-membered non-aromatic hydrocarbon ring is fused with phenyl group
- aromatic-aliphatic hydrocarbon group examples include an aralkyl group having 7-14 carbon atoms (C 6 - ⁇ 0 aryl-C ⁇ _ 4 alkyl group) such as phenyl-C ⁇ - 4 alkyl group, e.g., benzyl, phenethyl, 1-phenylethyl, 1-phenylpropyl, 2- phenylpropyl, 3-phenylpropyl, etc.; naphthyl-C ⁇ _ 4 alkyl group such as ⁇ -naphthylmethyl, ⁇ -naphthylethyl, ⁇ - naphthylmethyl, ⁇ -naphthylethyl, etc.; C 6 - ⁇ o aryl-C 2 - alkenyl group such as phenyl-C 2 - 4 alkenyl group, e.g., styryl, cinnamyl, etc.; and the like.
- hydrocarbyl group may have a substituent at a substitutable position.
- substituents include a halogen, nitro, cyano, oxo, (1) an optionally substituted heterocyclic group, (2) an optionally substituted sulfinyl group, (3) an optionally substituted sulfonyl group, (4) optionally substituted hydroxyl group, (5) optionally substituted thiol group, (6) an optionally substituted amino group, (7) an acyl group, (8) an optionally esterified or amidated carboxyl group, (9) an optionally substituted phosphoryl group, or the like.
- Examples of the substituent of above-mentioned (2) an optionally substituted sulfinyl group, (3) an optionally substituted sulfonyl group, (4) optionally substituted hydroxyl group, (5) optionally substituted thiol group and (6) an optionally substituted amino group include an optionally substituted hydrocarbyl.
- Examples of "hydrocarbyl" of such optionally substituted hydrocarbyl include those exemplified above. Such hydrocarbyl may be substituted by one or more substituents at a substitutable position.
- Examples of the substituent group of the optionally substituted hydrocarbyl as a substituent group include halogen, nitro, cyano, hydroxyl, thiol, amino and carboxyl .
- C ⁇ _ 6 alkylsulfinyl e.g., methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl etc.
- C 6 _ ⁇ 0 arylsulfinyl e.g., phenylsulfinyl, naphthylsulfinyl etc.
- C ⁇ _ 6 alkylsulfonyl e.g., methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl etc.
- C ⁇ -io arylsulfonyl e.g., phenylsulfonyl, naphthylsulfonyl etc.
- hydroxyl, C ⁇ _ 6 alkoxy e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, etc.
- C 6 - ⁇ o aryloxy e.g., phenoxy, naphthoxy, etc.
- thiol As the optionally substituted thiol group of above- mentioned (5), specifically, thiol, C ⁇ -6 alkylthio (e.g., methylthio, ethylthio, propylthio, etc.) and C 6 - ⁇ o arylthio (e.g., phenylthio, naphthylthio etc.) are exemplified.
- C ⁇ -6 alkylthio e.g., methylthio, ethylthio, propylthio, etc.
- C 6 - ⁇ o arylthio e.g., phenylthio, naphthylthio etc.
- amino, mono-C ⁇ - 6 alkylamino e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino etc.
- di-C ⁇ - 6 alkylamino e.g., dimethylamino, diethylamino, ethylmethylamino, dipropylamino, diisopropylamino, dibutylamino etc.
- examples of the acyl group of above-mentioned (7) include the same group as the acyl for R 5 .
- ester group or amide group of the optionally esterified or amidated carboxyl group of above- mentioned (8) examples include ester group with the same optionally substituted hydrocarbyl as the substituent of optionally substituted hydroxyl group of above-mentioned (4) or amide group with optionally substituted amino group of above- mentioned (6) .
- carboxyl specifically, carboxyl, C ⁇ _ 6 alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert- butoxycarbonyl etc.), C 6 - ⁇ o aryloxy-carbonyl (e.g., phenoxycarbonyl etc.), C- ⁇ e aralkyloxy-carbonyl (e.g., benzyloxycarbonyl, phenetyloxycarbonyl etc.), and the like are exemplified.
- C ⁇ _ 6 alkoxy-carbonyl e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert- butoxycarbonyl etc.
- C 6 - ⁇ o aryloxy-carbonyl e.g., phenoxycarbonyl etc.
- C- ⁇ e aralkyloxy-carbonyl e.g., benzyloxycarbonyl, phen
- carbamoyl mono-C_6 alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamo ' yl etc.), di-C ⁇ _ 6 alkyl- carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl etc.), C6- ⁇ o aryl-carbamoyl (e.g., phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl etc.), 5- to 6-membered heterocyclic carbamoyl (e.g., 2- pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-thienylcarbamo
- Examples of the "acyl" represented by R 5 of the formula : -NR 5 - include a formyl and a group where the carbonyl group is combined with a C ⁇ _ ⁇ 0 alkyl group, a C 2 _ ⁇ 0 alkenyl group, a C 2 - ⁇ o alkynyl group, a C3_ 7 cycloalkyl group, a C 5 _ 7 cycloalkenyl group or an aromatic group (e.g., phenyl group, pyridyl group, etc.) (e.g., acetyl, propionyl, butyryl, isobytyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crot
- R 5 is preferably hydrogen, C ⁇ _ ⁇ 0 alkyl, C 2 - ⁇ o alkenyl, C 2 - ⁇ o alkynyl, and more preferably hydrogen, C ⁇ _ ⁇ 0 alkyl.
- X represents a nitrogen and R 6 represents a hydrogen, an optionally substituted hydrocarbyl or an acyl .
- R ⁇ examples include the same groups as those exemplified with respect to the optionally substituted hydrocarbyl and acyl in R 5 .
- R 6 is preferably hydrogen, C ⁇ -10 alkyl, C 2 - ⁇ o alkenyl, C 2 - 10 alkynyl, and more preferably hydrogen, C ⁇ _ ⁇ 0 alkyl.
- R 1 and R la in the formula (I) and (la) are (1) an amino substituted by two substituents selected from an optionally substituted hydrocarbyl group and an optionally substituted heterocyclic group, or (2) an optionally substituted cyclic amino, provided that the cyclic amino has no carbonyl adjacent to the nitrogen in the formula (I).
- Examples of the "optionally substituted hydrocarbyl group" in the “amino substituted by two substituents selected from an optionally substituted hydrocarbyl group and an optionally substituted heterocyclic group” include the same groups as those exemplified with respect to the optionally substituted hydrocarbyl group of R 5 .
- Examples of the "optionally substituted heterocyclic group” in the “amino substituted by two substituents selected from an optionally substituted hydrocarbyl group and an optionally substituted heterocyclic group” include the same groups as those exemplified below with respect to the optionally substituted heterocyclic group of R .
- cyclic amino in the “optionally substituted cyclic amino” include, for example, a 3- to 7- membered cyclic amino group such as aziridino, pyrrolidino, imidazolidino, oxazolidino, thiazolidino, piperidino, 1,2- dihydropyridyl, 1, 2, 3, 6-tetrahydropyridyl, piperazino, morpholino, thiomorpholino and the like.
- the cyclic amino group may be substituted with 1 to 3 substituents selected from the group consisting of halogen, C ⁇ _ 6 alkyl, C 2 _ 6 alkenyl, C ⁇ _ 6 alkoxy-C ⁇ _ 6 alkyl, C 5 _ 7 cycloalkyl, C 6 - ⁇ o aryl (said aryl may have 1 or 2 substituents selected from halogen, C ⁇ - 6 alkyl, halogeno C ⁇ -6 alkyl and C ⁇ _ 6 alkoxy) , C 7 _
- aralkyl may have 1 or 2 substituents selected from halogen, C ⁇ _ 6 alkyl, halogeno C ⁇ _ 6 alkyl and C ⁇ - 6 alkoxy) , hydroxy, hydroxy-C ⁇ - 6 alkyl, C ⁇ -io aryloxy (said aryloxy may have 1 or 2 substituents selected from halogen, C ⁇ _ 6 alkyl, halogeno C ⁇ -6 alkyl and C ⁇ _ 6 alkoxy) , C 7 -i4 aralkyloxy, C ⁇ -io aryl-carbonyl, carboxyl, C ⁇ _ 6 alkoxy- carbonyl, carbamoyl, C6-10 aryl-carbamoyl, amino, C6-10 aryl- carbonylamino, C ⁇ _ 6 alkyl-carbonylamino, C ⁇ _ 6 alkoxy- carbonylamino, C 6 - ⁇ o arylthio, C 6 - ⁇ o
- R 1 and R la in the formula (I) and (la) are preferably an amino substituted by two substituents selected from optionally substituted C ⁇ _ 4 alkyl and optionally substituted phenyl, more preferably amino substituted by ' two optionally substituted C 1 - 4 alkyl groups.
- Preferred examples of the optionally substituted C 1 -. 4 alkyl and optionally substituted phenyl are those unsubstituted or those substituted with a group selected from the group consisting of hydroxy, C 1 -4 alkoxy; amino, mono- or di- C 1 - 4 alkyl amino; halogen; and pyridyl.
- R 2 in the formula (I) and (la) are alkyl, an optionally substituted cycloalkyl, an optionally substituted, cycloalkenyl, an optionally substituted aryl or an optionally substituted heterocyclic.
- alkyl for R 2 include a C ⁇ - 8 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, heptyl, octyl, etc.
- cycloalkyl for “optionally substituted cycloalkyl” of R 2 include a C 3 - 7 cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
- Examples of the "cycloalkenyl" for the "optionally substituted cycloalkenyl” of R 2 include a C 3 _ 7 cycloalkenyl group such as 1-cyclopentenyl, 2-cyclopentenyl, 3- cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-- cyclohexenyl, 1-cycloheptenyl, 2-cycloheptenyl, 3- cycloheptenyl, etc.
- each of the heterocyclic groups exemplified in (i) to (iii) may be a saturated or unsaturated heterocyclic group and the unsaturated heterocyclic group may be either aromatic or non-aromatic.
- heterocyclic for an optionally substituted heterocyclic of R 2 examples include an aromatic monocyclic heterocyclic group and a non-aromatic heterocyclic group.
- Specific examples of the heterocyclic for an optionally substituted heterocyclic include (i) an aromatic monocyclic heterocyclic group (e.g., furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 3, 4-oxadiazolyl, furazanyl, 1, 2, 3-thiadiazolyl, 1,2,4- thiadiazolyl, 1, 3, 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2,4- triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triaziny
- cycloalkyl may have the same substituent as those exemplified with respect to the optionally substituted hydrocarbyl group of R 5 and further may have the same group as optionally substituted hydrocarbyl group of R 5 as their substituent.
- two of the substituents of R 2 may be combined each other to form a ring.
- the ring examples include, for example, an aromatic fused heterocyclic group such as 8- to 12-membered aromatic fused heterocyclic group (preferably, heterocyclic group consisting of the above- mentioned 5- or 6-membered aromatic monocyclic heterocyclic group fused with a benzene ring or heterocyclic group consisting of the above-mentioned 5- or 6-membered aromatic monocyclic heterocyclic group fused with the same or different above-mentioned 5- or 6-membered aromatic monocyclic heterocyclic group), etc. (e.g., an aromatic fused heterocyclic group such as 8- to 12-membered aromatic fused heterocyclic group (preferably, heterocyclic group consisting of the above- mentioned 5- or 6-membered aromatic monocyclic heterocyclic group fused with a benzene ring or heterocyclic group consisting of the above-mentioned 5- or 6-membered aromatic monocyclic heterocyclic group fused with the same or different above-mentioned 5- or 6-membered aromatic monocyclic heterocycl
- R 2 is preferably an optionally substituted phenyl or an optionally substituted 5- to 6- membered heterocyclic group.
- R 1 is CR 3a or a nitrogen
- Y 2 is CR 3b or a nitrogen
- Y 3 is CR 3c or a nitrogen (wherein R 3a , R 3b and R 3c are independently a hydrogen, a halogen, a nitro, an optionally substituted hydrocarbyl, an optionally substituted hydrocarbyloxy, an optionally
- the 6-membered ring with Y 1 , Y 2 and Y 3 of the formula (I) and (la) is a ring containing one or less nitrogen atom such as benzene ring and pyridine ring.
- halogen include fluorine, chlorine, bromine, iodine, and the like, preferably, fluorine and chlorine.
- Examples of the "optionally substituted hydrocarbyl" in R 3a , R 3b and R 3c include the same groups as those exemplified with respect to the optionally substituted hydrocarbyl group of R 5 .
- Examples of the hydrocarbyl for said "optionally substituted hydrocarbyloxy" and “optionally substituted hydrocarbylthio" of R 3a , R 3b and R 3c include the same groups as those exemplified with respect to the optionally substituted hydrocarbyl group of R 5 .
- Examples of the "optionally substituted amino" for R 3a , R 3b and R 3c include amino group, an N-mono-substituted amino group, and an N, N-di-substituted amino group.
- substituted amino groups include that having one or two substituents of an optionally substituted hydrocarbyl group (e.g., a C ⁇ _ 8 alkyl group, a C 3 - 7 cycloalkyl group, a C_ 8 alkenyl group, a C 2 _ 8 alkynyl group, a C 3 - 7 cycloalkenyl group, a C 6 - ⁇ o aryl group that may have a C ⁇ _ alkyl group, etc.), an optionally substituted heterocyclic group (e.g., the same group as an optionally substituted heterocyclic group of R 2 ) , or the formula: -COR 3 (wherein R 3d represents hydrogen atom or an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group.
- an optionally substituted hydrocarbyl group e.g., a C ⁇ _ 8 alkyl group, a C 3 - 7 cycloalkyl group, a C_ 8 alkenyl
- the hydrocarbyl group” or “the heterocyclic group” in “an optionally substituted hydrocarbyl group” or “an optionally substituted heterocyclic group” of R 3d may have the same substituent as that of "the hydrocarbyl group” or “the heterocyclic group” in “an optionally substituted hydrocarbyl” of R 5 or “an optionally substituted heterocyclic” of R 2 ) , preferably a C ⁇ - ⁇ o acyl group (e.g., a C 2 _ 7 alkanoyl, benzoyl, nicotinoyl, etc.).
- a C ⁇ - ⁇ o acyl group e.g., a C 2 _ 7 alkanoyl, benzoyl, nicotinoyl, etc.
- the two groups in said substituted amino groups may be combined to form a nitrogen-containing 5- to 7-membered ring (e.g., piperidino, piperazino, morpholino, thiomorpholino, etc.).
- acyl for R 3a , R 3b and R 3c examples include the same groups as those exemplified with respect to the acyl for R 5 .
- Y 1 , Y 2 and Y 3 are preferably CR 3a , CR 3b and CR 3c respectively.
- R 3 , R 3b and R 3c are preferably hydrogen, C 1 -. 4 alkyl and C ⁇ _ 4 alkoxy.
- W is a bond, -(CH 2 )n- or -(CH 2 )m-C0-, and n is 1-4 and m is 0-4.
- W is a bond.
- Z is a bond, -CO-, an oxygen, a sulfur, -SO-, -S0 2 -, -NR 4 -, -NR 4 -alk-, -CONR 4 - or -NR 4 C0- .
- Said alk is an optionally substituted C 1 - 4 alkylene such as methylene, ethylene, propylene, butylene and the like .
- R 4 is a hydrogen, an optionally substituted hydrocarbyl or an acyl.
- the "optionally substituted hydrocarbyl” and “acyl” for R 4 include the same groups as those exemplified with respect to the optionally substituted hydrocarbyl group and acyl for R 5 .
- Z is -NR 4 - (wherein R 4 is as defined above).
- R 4 are hydrogen and C 1 - 4 alkyl.
- the fused ring of the formula (I) is preferably an imidazopyridine ring.
- the compounds wherein ring A is the 5- membered ring of the formula A' (wherein X is a carbon and X 1 is a sulfur) , W is a bond, Z is -NHCO- or -CONH- and Y 1 is CR 3a (wherein R 3a is a hydrogen, a halogen or an alkoxy) are excluded from the compounds of the formula (I) and (la) , and further the compounds wherein ring A is the 5-membered ring of the formula A' (wherein X is a carbon and X 1 is an oxygen, a sulfur or -NH-) , R 1 is an optionally substituted 1-piperazinyl, W is a bond, Z is a bond, R 2 is an optionally substituted aryl) are excluded from the compounds of the formula (I) .
- Compound (I) or (la) may be in the form of a prodrug thereof.
- the prodrug of Compound (I) or (la) refers to a compound that is converted into Compound (I) or (la) by a reaction with an enzyme, gastric acid, or the like under a physiological condition in the living body, namely, (i) a compound that is converted into Compound (I) or (la) by an enzymatic oxidation, reduction, hydrolysis, or the like, and (ii) a compound that is converted into Compound (I) or (la) by hydrolysis with gastric acid or the like.
- Examples of a prodrug of Compound (I) or (la) to be used include a compound or its salt wherein hydroxyl group in Compound (I) or (la) is acylated, alkylated, phosphorylated, or converted into borate (e.g., a compound or its salt wherein hydroxyl group in Compound (I) or (la) is converted into acetyloxy, palmitoyloxy, propanoyloxy, pivaloyloxy, succinyloxy, fumaryloxy, alanyloxy, dimethylaminomethylcarbonyloxy, etc.), a compound or its salt wherein carboxyl group in Compound (I) or (la) is esterified or amidated (e.g., a compound or its salt wherein carboxyl group in Compound (I) or (la) is subjected to ethyl esterification, phenyl esterification, carboxyoxymethyl esterification, dimethylaminomethyl esterification, pivaloy
- prodrugs can be produced according to a per se known method or its modified method.
- a prodrug of Compound (I) or (la) may be a compound or its salt that is converted into Compound (I) or (la) under physiological conditions as described in
- Step B-2 (la) wherein R la , R lb are independently optionally substituted hydrocarbyl groups, or R la and R lb may be optionally substituted cyclic form, R laa , R lbb , R lcc and R ldd are independently hydrogen or optionally substituted hydrocarbyl groups, or R laa and R lbb or R lcc and R ldd may be optionally substituted cyclic form, L 1 is a leaving group (e.g.
- step A compound (III) or a salt thereof can be prepared by hydrogenation of compound (II) or a salt thereof in the presence of a hydrogenation catalyst, or prepared by a reduction reaction for compound (II) or a salt thereof.
- a palladium catalyst such as palladium black, palladium oxide, palladium barium sulfate, palladium on carbon, palladium hydroxide, a platinum catalyst such as platinum black, platinum oxide and platinum on carbon, or nickel catalyst such as reduced nickel, oxidized nickel, Raney nickel are used.
- any solvents can be used as long as they do not inhibit the reaction.
- alcohols e.g.
- C 1 -3 alcohol such as methanol, ethanol, propanol and the like
- ethers diethyl ether, diisopropyl ether, ethylene glycol dimethyl ether, tetrahydrofuran, dioxane, etc.
- esters ethyl acetate, etc.
- the reaction temperature is 0 °C to 200 °C, preferably 20 °C to 100 °C.
- the reaction time is usually 0.5 to 48 hours, preferably 1 to 16 hours. While a reaction is usually performed at atmospheric pressure, it can be performed under pressure (3 to 10 atom) if necessary.
- a catalyst employed may vary depending on the type of the catalyst employed, it is usually 0.1 to 20% by weight based on an active intermediate or a salt thereof.
- Compound (III) or a salt thereof can be also prepared by reduction of compound (II) or a salt thereof.
- a reducing agent is preferably Fe, Zn, Sn or SnCl 2 . This reaction may be performed under acidic conditions.
- An acid employed in this reduction may for example be an inorganic acid such as hydrochloric acid, sulfuric acid and nitric acid, etc., and an ordinary organic acid such as formic acid, acetic acid, trifluoroacetic acid and methanesulfonic acid, etc. as well as a Lewis acid.
- a reaction solvent may for example be alcohols such as methanol and ethanol, etc., ethers such as dioxane and tetrahydrofuran, etc., aromatic hydrocarbons such as benzene, toluene and xylene, etc., esters such as ethyl acetate, etc., halogenated hydrocarbons such as chloroform and dichloromethane, etc., nitriles such as acetonitrile, etc., amides such as N,N-dimethylformamide and N,N- dimethylacetamide, etc. and sulfoxides such as dimethylsulfoxide, etc. These solvents may be used by mixing at an appropriate ratio. While the reaction temperature may vary depending on the substrate employed as well as other conditions, it is -
- Compound (II) or (III) or a salt thereof can be produced by Schemes 2 to 9.
- the thus obtained compound (II) or (III) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- R la is equal to R lb in compound (la)
- a reducing agent is preferably sodium borohydride, lithium borohydride, sodium cyanoborohydride and sodium triacetoxyborohydride .
- a hydrogenation catalyst is preferably a palladium catalyst ⁇ such as palladium black, palladium oxide, palladium barium sulfate, palladium on carbon, palladium hydroxide, a platinum catalyst such as platinum black, platinum oxide and platinum on carbon, or nickel catalyst such as reduced nickel, oxidized nickel or Raney nickel.
- the reaction solvent may for example be alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N-dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio. When producing an imine, use of molecular sieves or addition of an acid serves to promote the reaction.
- An acid employed here is preferably acetic acid and trifluoroacetic acid, etc. While the reaction temperature in this imine production may vary depending on compound (III) or a salt thereof as well as other conditions, it is 0 to 200 °C, preferably 0 to 150 °C. The reaction time is 30 minutes to 48 hours, preferably 1 hour to 24 hours. The reaction temperature in the reducing reaction is -
- Compound (la) or a salt thereof can be also prepared by reacting compound (III) with R ⁇ L 1 or R ⁇ L 1 .
- R ⁇ L 1 may be used in step B-2.
- the alkylation reactions may be performed stepwise by R ⁇ L 1 and
- step B-2 1 to 10 moles, preferably 1 to 5 moles of a compound represented by R ⁇ L 1 or a salt thereof and 1 to
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide and sodium ethoxide, etc., an a ine such as trimethylamine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc.
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- reaction temperature may vary depending on compound (III) or a salt, thereof employed as well as other reaction conditions, it is -20 to 200 °C, preferably 0 to 150 °C.
- the reaction time is 5 minutes to 48 hours, preferably 5 minutes to 24 hours.
- Alkylation of compound (III) to prepare compound (la) may be performed by combined reactions of steps B-1 and B-2.
- the thus obtained compound (la) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Z 1 is oxygen, sulfur, -NR 4 -, or -NR-alk-
- Z la is - SO- or -S0 2 -
- W 2 is N0 2 or NH 2
- L 1 is a leaving groups (e.g. halogen atom such as chlorine, bromine and iodine, etc, sulfonyloxy group such as p-toluenesulfonyloxy group, methanesulfonyloxy group and trifluoromethanesulfonyloxy group, and acyloxy group such as acetyloxy group and benzoyloxy group) and each of other symbols has a meaning defined above.
- halogen atom such as chlorine, bromine and iodine, etc
- sulfonyloxy group such as p-toluenesulfonyloxy group, methanesulfonyloxy group and trifluoromethanesulfonyloxy group
- Compound (lla) which is encompassed within compound (II) or (III) , or a salt thereof can be prepared by reacting compound (IV) with R 2 Z 1 H.
- Compound (IV) or a salt thereof can be prepared by Schemes 10 or 11 described below.
- step C-l 1 to 5 moles, preferably 1 to 3 moles of a compound represented by R 2 Z 1 H or a salt thereof and 1 to
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide and sodium ethoxide, etc., an amine such as trimethylamine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc.
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio . While the reaction temperature may vary depending on compound (IV) or a salt thereof employed as well as other reaction conditions, it is -20 to 200 °C, preferably 0 to
- reaction time is 5 minutes to 48 hours, preferably 5 minutes to 24 hours.
- Z 1 is -NR 4 -, or -NR 4 -alk- in R 2 Z 1 H, compound
- step C-2 1 to 10 moles, preferably 1 to 5 moles of oxidation agent are employed per 1 mole of compound (lla) or a salt thereof.
- This reaction may be performed under acidic conditions.
- An acid employed in this oxidation may for example be an inorganic acid such as hydrochloric acid, sulfuric acid and nitric acid, etc., and an ordinary organic acid such as formic acid, acetic acid, trifluoroacetic acid and methanesulfonic acid, etc. as well as a Lewis acid.
- a reaction solvent may for example be water, alcohols such as methanol and ethanol, etc., ethers such as dioxane and tetrahydrofuran, etc., aromatic hydrocarbons such as benzene, toluene and xylene, etc., esters such as ethyl acetate, etc., halogenated hydrocarbons such as chloroform and dichloromethane, etc., nitriles such as acetonitrile, etc., amides such as N,N-dimethylformamide and N,N- dimethylacetamide, etc. and sulfoxides such as dimethylsulfoxide, etc. These solvents may be used by mixing at an appropriate ratio. While the reaction temperature may vary depending on the substrate employed as well as other conditions, it is -
- the reaction time is usually 5 minutes to 24 hours, preferably 5 minutes to 10 hours.
- the thus obtained compound (Ila) and (Ilaa) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Compound (lib) which is encompassed within compound (II) or (III) , or a salt thereof can be prepared by reacting compound (IV) with a boronic acid R 2 B(OH) 2 or boronic acid esters or a salt thereof in the presence of a palladium catalyst, preferably tetrakis (triphenylphosphine) palladium (0) and a base according to the procedure of Suzuki coupling (Organic Synthesis via Boranes, vol. 3: Suzuki coupling, A.Suzuki and H.C. Brown, Aldrich, 2002).
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide and sodium ethoxide, etc., an amine such as trimethyla ine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc.
- solvent having no adverse effect on the reaction examples include water, alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- reaction temperature may vary depending on compound (IV) or a salt thereof employed as well as other reaction conditions, it is -20 to 200 °C, preferably 40 to 150 °C.
- the reaction time is 5 minutes to 48 hours, preferably lh to 24 hours.
- the thus obtained compound (lib) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step E an organic metal reagent is employed in an amount of 1 to 5 moles, preferably 1 to 3 moles per 1 mole of compound (IV) or a salt thereof.
- An organic metal reagent may preferably be organic lithium such as n-BuLi, sec-BuLi, tert-BuLi, etc.
- solvent having no adverse effect on the reaction include ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio . While the reaction temperature may vary depending on the reagent employed as well as other conditions, it is -
- the thus obtained compound (lie) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step F-l compound (VI) or a salt thereof can be prepared from compound (V) or a salt thereof and an aldehyde compound R 4 CH0 by an in situ production of an imine, which is then reduced by an appropriate reducing agent.
- the reaction can be carried out similar to step B in Scheme 1 to prepare compound (VI) .
- Compound (V) or a salt thereof can be prepared by Scheme 10 described below.
- step F-2 compound (VI) or a salt thereof can be also prepared by reacting (V) with R 4 L 2 or a salt thereof.
- This reaction is carried out in the presence of a base in a solvent having no adverse effect on the reaction according to the conventional method.
- leaving groups L 2 include halogen atom such as chlorine, bromine and iodine, sulfonyloxy group such as p- toluenesulfonyloxy group, methanesulfonyloxy group and trifluoromethanesulfonyloxy group, and acyloxy group such as acetyloxy group and benzoyloxy group.
- Example of the base include alkali metal salts such as potassium hydroxide, sodium hydroxide, sodium bicarbonate and potassium carbonate; amines such as pyridine, triethylamine, N,N-dimethylaniline and 1,8- diazabicyclo [5.4.0] undec-7-ene; metal hydrides such as potassium hydride and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide and potassium t-butoxide.
- An amount of these bases to be used is preferably about 1 to about 5 equivalents relative to compound (V) .
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, aromatic hydrocarbon such as benzene, toluene and xylene; ethers such as tetrahydrofuran, dioxane and diethyl ether; amides such as N,N-dimethylformamide; and sulfoxides such as dimethyl sulfoxide. These solvents may be used by mixing at an appropriate ratio.
- a reaction temperature is usually about -50 to about 150°C, preferably -10°C to 120°C.
- a reaction time is usually 0.5 to 20 hours.
- step G compound (lid) is prepared by reacting a calboxylc acid R 2 COOH or a reactive derivative at a carboxyl group thereof and a salt thereof with compound
- (VI) or a reactive derivative at an amino group thereof or a salt thereof examples include Schiff base type imine produced by reaction of compound (VI) with a carbonyl compound such as aldehyde, ketone and the like; silyl derivative produced by a reaction of compound (VI) and a silyl compound such as bis (trimethylsilyl) acetamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl) urea and the like; derivative produced by a reaction of compound (VI) with phosphorus trichloride or phosgene.
- a carbonyl compound such as aldehyde, ketone and the like
- silyl derivative produced by a reaction of compound (VI) and a silyl compound such as bis (trimethylsilyl) acetamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl) urea and the like
- the suitable reactive derivative at a carboxyl group of R 2 COOH include acid halide, acid anhydride, activated amide, activated ester and the like.
- the suitable reactive derivative include: acid chloride; acid azide; mixed acid anhydride with an acid such as substituted phosphoric acid such as dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid and the like, dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid such as methanesulfonic acid and the like, aliphatic carboxylic acid such as acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, trichloroacetic acid and the like or aromatic carboxylic acid such as benzoic acid and the like; symmetric acid anhydride; activated amide with
- reactive derivatives can be arbitrarily selected depending on a kind of compound (VI) to be used.
- suitable reactive derivative of compound (lid) include alkali metal salts such as sodium salt, potassium salt and the like, alkaline earth metal salts such as calcium salt, magnesium salt and the like, and basic salts such as organic base salts such as ammonium salt, trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N-dibenzylethylenediamine salt and the like.
- reaction is usually carried out in the conventional solvent such as water, alcohols such as methanol, ethanol and the like, acetone, dioxane, acetonitrile, chloroform, dichloromethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide and pyridine
- solvents may be used as a mixture with water.
- R 2 COOH When R 2 COOH is used as the form of a free acid or a salt thereof in this reaction, it is desirable that the reaction is carried out in the presence of the normally used condensing agent such as so-called Vilsmeier regent and the like prepared by a reaction of N,N'- dicyclohexylcarbodiimide; N-cyclohexyl-N' - morpholinoethylcarbodiimide; N-cyclohexyl-N' - (4- diethylaminocyclohexyl) carbodiimide; N,N'- diethylcarbodiimide, N,N' -diisopropylcarbodiimide, N-ethyl- N' - (3-dimethylaminopropyl) carbodiimide; N,N' -carbonylbis (2- methylimidazole) ; pentamethyleneketene-N-cyclohexylimine; diphenyl
- reaction may be carried out in the presence of an inorganic base or an organic base such as alkali metal bicarbonate salt, tri (lower) alkylamine, pyridine, N- (lower) alkylmorpholine, N,N-di (lower) alkylbenzylamine and the like.
- a reaction temperature is not particularly limited, but the reaction is carried out under cooling or under warming.
- An amount of R 2 COOH to be used is 1 to 10 mole equivalent, preferably 1 to 3 equivalent relative compound (VI) .
- a reaction temperature is usually -30°C to 100°C.
- a reaction time is usually 0.5 to 20 hours.
- a mixed acid anhydride is used,
- R 2 COOH and chlorocarbonic ester e.g. methyl chlorocarbonate, ethyl chlorocarbonate, isobutyl chlorocarbonate etc.
- compound (VI) e.g. triethylamine, N-methylmorpholine, N,N- dimethylaniline, sodium bicarbonate, sodium carbonate, potassium carbonate etc.
- An amount of R 2 COOH to be used is usually 1 to 10 mole equivalent, preferably 1 to 3 mole equivalent relative to compound (VI) .
- a reaction temperature is usually -30°C to 100°C.
- a reaction time is usually 0.5 to 20 hours.
- the thus obtained compound (lid) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Step H can be carried out similar to step G in Scheme 5 to prepare compound (He) which is encompassed within compound (II) or (III), or a salt thereof.
- Compound (VII) or a salt thereof can be prepared by Scheme 12 described below.
- Compound (Hf) which is encompassed within compound (II) or (III), or a salt thereof can be prepared by treatment of compound (Villa) with a halogenation agent.
- Compound (Villa) or a salt thereof can be prepared by Schemes 13 or 14 described below.
- the halogenation agent include chlorine, bromine, iodine, thionyl chloride, thionyl bromide,, sulfuryl chloride, oxalyl chloride, phosphorus trichloride, phosphorous pentachloride, and phosphorous oxychloride, etc.
- the halogenation agent is employed in an amount of 1 to 10 moles, preferably 1 to 3 moles per 1 mole of compound (Villa) or a salt thereof.
- the solvent having no adverse effect on the reaction include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide.
- reaction temperature may vary depending on the reagent employed as well as other conditions, it is -20 to 200 °C, preferably 20 to 100 °C.
- the reaction time is 5 minutes to 48 hours, preferably 30 minutes to 24 hours.
- the thus obtained compound (Ilf) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Scheme 8 wherein each of symbols has a meaning defined above.
- Compound (Hg) which is encompassed within compound (II) or (III) , or a salt thereof can be prepared by treatment of compound (Vlllb) with a dehydrothiolation agent.
- Compound (Vlllb) or a salt thereof can be prepared by Schemes 13 or 14 described below.
- dehydrothiolation agent examples include N,N'- dicyclohexylcarbodiimide, N-cyclohexyl-N' ' - morpholinoethylcarbodiimide, N-cyclohexyl-N' - (4- diethylaminocyclohexyl) carbodiimide, N,N' - diethylcarbodiimide, N,N' -diisopropylcarbodiimide, N-ethyl-
- the dehydrothiolation agent is employed in an amount of 1 to 10 moles, preferably 1 to 3 moles per 1 mole of compound (Vlllb) or a salt thereof.
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- the reaction may be carried out in the presence of an inorganic base or an organic base such as alkali metal salts such as potassium hydroxide, sodium hydroxide, sodium bicarbonate and potassium carbonate; amines such as pyridine, triethylamine, N,N-dimethylaniline and 1,8- diazabicyclo [5.4.0] undec-7-ene; metal hydrides such as potassium hydride and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide and potassium t-butoxide.
- an inorganic base or an organic base such as alkali metal salts such as potassium hydroxide, sodium hydroxide, sodium bicarbonate and potassium carbonate; amines such as pyridine, triethylamine, N,N-dimethylaniline and 1,8- diazabicyclo [5.4.0] undec-7-ene; metal hydrides such as potassium hydride and sodium hydride; and alkali metal alkoxides such
- the reaction time is 5 minutes to 10 hours, preferably 5 minutes to 2 hours.
- the thus obtained compound (Ilg) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step L compound (X) or a salt thereof can be prepared by treatment of compound (IX) with ammonia.
- Compound (IX) or a salt thereof is mainly commercially available, or can be prepared by reacting thiophosgene with the amino derivatives (XIV) described below (Scheme 13) .
- the solvent examples include water, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N-dimethylacetamide, and sulfoxidse such as dimethylsulfoxide. These solvent may be used by mixing at an appropriate ratio. While the reaction temperature may vary depending on the reagent employed as well as other conditions, it is -20 to 200 °C, preferably 20 to 100 °C.
- the reaction time is 5 minutes to 48 hours, preferably 30 minutes to 24 hours.
- the thus obtained compound (X) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Step M can be carried out according to steps I, J or K in the Schemes 7 to 9 to prepare compound (V) .
- step N an amino group of compound (V) is converted into a diazonium salt, and halogenation agent is reacted thereon, according to the procedure of Sandmeyer reaction, to prepare compound (IVa), which is encompassed within compound (IV) .
- Diazonization in the present method is carried out in the presence of an acid in a solvent having no adverse effect on the reaction according to the conventional method.
- the acid for example, acetic acid and hydrochloric acid are used.
- a diazotizing agent sodium nitrite, alkyl nitrite or sulfated nitrosyl is used.
- the thus obtained diazonium salt of compound (V) is reacted with halogenation agent to prepare compound (IV) .
- the halogenation agent include chlorine, bromine, iodine, copper (I) bromide, copper (II) bromide, copper (I) chlolide and copper (II) chloride, etc.
- solvent examples include water, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N-dimethylacetamide, and sulfoxidse such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- a reaction temperature is usually about -50°C to about 150°C, preferably about -10°C to about 100°C.
- reaction time is usually about 0.5 to about 20 hours.
- the thus obtained compound (IVa) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step 0 compound (XII) or a salt thereof can be prepared by treatment of compound (XI) with 1, 1' -carbonyl diimidazole, phosgene, alkyl haloformate such as ethyl chloroformate, phenyl haloformate such as phenyl chloroformate or urea, etc.
- Compound (XI) or a salt thereof is mainly commercially available or can be prepared from the nitro derivatives corresponded to compound (XI) .
- the solvent examples include ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N-dimethylacetamide, and sulfoxidse such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio. While the reaction temperature may vary depending on the reagent employed as well as other conditions, it is -20 to 200 °C, preferably 20 to 100 °C.
- the reaction time is 5 minutes to 48 hours, preferably 30 minutes to 24 hours.
- the thus obtained compound (XII) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step P after base treatment of compound (XII) , the resulting moiety may be converted to a leaving group to prepare compound (IV) .
- Such leaving group may for example be a substituted sulfonyloxy (for example, methanesulfonyloxy and p- toluenesulfonyloxy, etc.), an acyloxy (for example, acetoxy and benzoyloxy, etc.) and an oxy group which is substituted with a heterocyclic or aryl group (such as succinimide, benzotriazole, quinoline and 4-nitrophenyl, etc.), etc.
- a substituted sulfonyloxy for example, methanesulfonyloxy and p- toluenesulfonyloxy, etc.
- an acyloxy for example, acetoxy and benzoyloxy, etc.
- an oxy group which is substituted with a heterocyclic or aryl group such as succinimide, benzotriazole, quinoline and 4-nitrophenyl, etc.
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide and sodium ethoxide, etc., an amine such as trimethylamine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc.
- step P compound (IV) or a salt thereof can be also prepared by treatment of compound (XII) with a halogenation agent.
- a halogenation agent include chlorine, bromine, iodine, thionyl chloride, thionyl bromide, sulfuryl chloride, oxalyl chloride, phosphorus trichloride, phosphorous pentachloride, and phosphorous oxychloride, etc.
- the halogenation agent is employed in an amount of 1 to 10 moles, preferably 1 to 3 moles per 1 mole of compound
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- reaction temperature may vary depending on the reagent employed as well as other conditions, it is -20 to 200 °C, preferably 20 to 100 °C.
- the reaction time is 5 minutes to 48 hours, preferably 30 minutes to 24 hours.
- the thus obtained compound (IV) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step Q an amino group of compound (V) is converted into a diazonium salt, and cyanation agent is reacted thereon to prepare compound (XIII), according to the procedure of Sandmeyer reaction.
- Diazotization in the present method is carried out in the presence of an acid in a solvent having no adverse effect on the reaction according to the conventional method.
- the acid for example, acetic acid, sulfuric acid and hydrochloric acid are used.
- a diazotizing agent sodium nitrite, alkyl nitrite or sulfated nitrosyl is used.
- the thus obtained diazonium salt of compound (V) is reacted with cyanation agent to prepare compound (XIII) .
- the cyanation agent include copper cyanide, potassium cyanide, sodium cyanide and nickel cyanide, etc.
- the solvent include water, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N-dimethylacetamide, and sulfoxides such as dimethylsulfoxide.
- a reaction temperature is usually about -50°C to about 150°C, preferably about -10°C to about 100°C.
- a reaction time is usually about 0.5 to about 20 hours.
- the thus obtained compound (XIII) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step R compound (VII) or a salt thereof can be prepared by hydrolysis of compound (XIII) or a salt thereof. It is preferable that hydrolysis is carried out in the presence of a base or an acid.
- An acid which may be employed may for example be an inorganic acid such as hydrochloric acid, sulfuric acid and nitric acid
- a base may for example be an inorganic base (alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc.).
- This reaction is conducted in a 20 to 50 volumes of an aqueous solution of an inorganic acid described above (usually at 10 to 30%) per 1 g of the nitrile compound (XIII) , or in an aqueous solution containing 3 to 10 moles of a base described above per 1 mole of the nitrile compound (XIII) .
- the reaction may be performed in an aqueous solution described above which is supplemented with an organic solvent.
- An organic solvent which may be employed is alcohols such as methanol and ethanol, organic acids such as acetic acid, etc., ethers, such as dioxane and tetrahydrofuran, a nitrile such as acetonitrile, amides such as N,N-dimethylformamide and N,N-dimethylacetamide and sulfoxides such as dimethylsulfoxide.
- the reaction temperature may vary depending on the nitrile employed as well as other conditions, it is 0 to 200 °C, preferably 20 to 150 °C.
- the reaction time is 30 minutes to 48 hours, preferably 1 to 24 hours.
- the thus obtained compound (VII) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Compound (VIII) or a salt thereof can be prepared by reacting (XIV) with R 2 NCS or a salt thereof.
- an isothiocyanate R 2 NCS is employed in an amount of 1 to 10 moles, preferably 1 to 3 moles per 1 mole of compound (XIV) or a salt thereof.
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- reaction temperature may vary depending on compound (XIV) employed as well as other conditions, it is 0 to 200 °C, preferably 20 to 150 °C.
- the reaction time is 30 minutes to 48 hours, preferably 1 to 24 hours.
- the thus obtained compound (VIII) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Compound (VIII) or a salt thereof can be also prepared by reacting (IX) with R 2 NH 2 or a salt thereof.
- step T compound R 2 NH 2 is employed in an amount of 1 to 10 moles, preferably 1 to 3 moles per 1 mole of compound (IX) or a salt thereof.
- Examples of the solvent having no adverse effect on the reaction include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- alcohols such as methanol and ethanol
- ethers such as dioxane and tetrahydrofuran
- aromatic hydrocarbons such as benzene, toluene and xylene
- esters such as ethyl acetate
- halogenated hydrocarbons such as chloroform and dichloromethane
- reaction temperature may vary depending on compound (IX) employed as well as other conditions, it is 0 to 200 °C, preferably 20 to 150 °C.
- the reaction time is 30 minutes to 48 hours, preferably 1 to 24 hours.
- the thus obtained compound (VIII) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- Step ⁇ can be carried out similar to step C, D, and E in the Schemes 2 to 4 to prepare compound (lb) which is encompassed within compound (I) .
- Compound (XV) or a salt thereof can be prepared by Scheme 16 described below.
- Compound (XVIII) or a salt thereof can be prepared by reacting compound (XVI) with compound (XVII) .
- step V 1 to 5 moles, preferably 1 to 3 moles of compound (XVII) or a salt thereof are employed per 1 mole of compound (XVI) or a salt thereof.
- Examples of the solvent having no adverse effect on the reaction include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio. This reaction may be performed under basic conditions.
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide and sodium ethoxide, etc., an amine such as trimethylamine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc. While the reaction temperature may vary depending on compound (XVII) or a salt thereof employed as well as other reaction conditions, it is -20 to 200 °C, preferably 0 to
- step X compound (XV) or a salt thereof can be prepared by treatment of compound (XIX) with a halogenation agent .
- halogenation agent examples include N- chlorosuccinimide, N-bromosuccinimide, chlorine, bromine, iodine, thionyl chloride, thionyl bromide, sulfuryl chloride, oxalyl chloride, phosphorus trichloride, phosphorous pentachloride, and phosphorous oxychloride, etc.
- the halogenation agent is employed in an amount of 1 to 10 moles, preferably 1 to 3 moles per 1 mole of compound (XIX) or a salt thereof.
- Examples of the solvent having no adverse effect on the reaction include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as carbon tetrachloride, chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N- dimethylformamide and N,N-dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- alcohols such as methanol and ethanol
- ethers such as dioxane and tetrahydrofuran
- aromatic hydrocarbons such as benzene, toluene and xylene
- esters such as ethyl acetate
- halogenated hydrocarbons such as
- reaction temperature may vary depending on the reagent employed as well as other conditions, it is -50 to 200 °C, preferably 0 to 100 °C.
- the reaction time is 5 minutes to 48 hours, preferably 30 minutes to 24 hours.
- the thus obtained compound (XV) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography. (Method C) Scheme 17
- Compound (lc) which is encompassed within compound (I) , or a salt thereof can be prepared by reacting compound (XX) with an amino compound R la R lb NH.
- Compound (XX) or a salt thereof can be prepared by the procedures described in Methods A and B.
- step Y 1 to 5 moles, preferably 1 to 3 moles of a compound represented by R la R lb NH or a salt thereof and 1 to 5 moles, preferably 1 to 3 moles of a base are employed per 1 mole of compound (XX) or a salt thereof.
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide and sodium ethoxide, etc., an amine such as trimethylamine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc.
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio .
- reaction temperature may vary depending on compound (XX) or a salt thereof employed as well as other reaction conditions, it is -20 to 200 °C, preferably 0 to 150 °C.
- the reaction time is 5 minutes to 48 hours, preferably 5 minutes to 24 hours.
- compound (lc) can be also prepared by reacting compound (XX) with R la R lb NH or a salt thereof in the presence of a palladium catalyst, preferably palladium (II) acetate and a catalytic amount of a phosphine ligand, preferably 2- (dicyclohexylphosphino) biphenyl, according to the procedure of Buchwald et al . (J. Am.
- step Z compound (XXII) is prepared by removing a carboxyl-protecting group.
- Compound (XXI) or a salt thereof can be prepared by the procedures described in Methods A, B,
- hydrolysis is carried out in the presence of a base or an acid.
- suitable base include inorganic bases such as alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide) , alkaline earth metal hydroxide (e.g. magnesium hydroxide and calcium hydroxide), alkali metal carbonate (e.g. sodium carbonate and potassium carbonate), alkaline earth metal carbonate (e.g. magnesium carbonate and calcium carbonate) , alkali metal bicarbonate (e.g.
- alkali metal acetate e.g. sodium acetate and potassium acetate
- alkaline earth metal phosphate e.g. magnesium phosphate and calcium phosphate
- alkali metal hydrogen phosphate e.g. disodium hydrogen phosphate and dipotassium hydrogen phosphate
- organic bases such as trialkylamine (e.g. trimethylamine and triethylamine) , picoline, N- methylpyrrolidine, N-methylmorpholine, 1 5- diazabicyclo [4.3.2] non-5-ene, 1, 4-diazabicyclo [2.2.2] non-5- ene and 1, 8-diazabicyclo [4.3.0] -7-undecene.
- Hydrolysis using a base is carried out in water or a hydrophilic organic solvent or a mixed solvent in many cases.
- a suitable acid include formic acid, hydrochloric acid, hydrobromic acid and sulfuric acid.
- the present hydrolysis reaction is usually carried out in an organic solvent, water or a mixed solvent thereof.
- a reaction temperature is not particularly limited, but is appropriately selected depending on a kind of a carboxyl- protecting group and an elimination method.
- Elimination using a Lewis acid is carried out by reacting compound (XXI) or a salt thereof with a Lewis acid, for example, trihalogenated boron (e.g. boron trichloride and boron trifluoride) , tetrahalogenated titanium (e.g.
- This elimination reaction is preferably carried _ out in the presence of a cation scavenger (e.g. anisole and phenol) and is usually carried out in a solvent such as nitroalkane (e.g. nitromethane and nitroethane), alkylene halide (e.g. methylene chloride and ethylene chloride) , diethyl ether, carbon disulfide, and a solvent having no adverse effect on the reaction.
- a cation scavenger e.g. anisole and phenol
- alkylene halide e.g. methylene chloride and ethylene chloride
- diethyl ether diethyl ether
- carbon disulfide e.g. a solvent having no adverse effect on the reaction.
- solvents may be used as a mixture thereof. It is preferable that elimination by reduction is applied to elimination of a protecting group such as halogenated alkyl (e.g. 2-iodoethyl and 2,2,2- trichloroethyl) ester, and aralkyl (e.g. benzyl) ester.
- a reduction method using in the present elimination reaction include the conventional catalytic reduction in the presence of a combination of a metal (e.g. zinc and zinc amalgam) or a salt of a chromium compound (e.g. chromate chloride and chromate acetate) and an organic or inorganic acid (e.g.
- reaction temperature is not particularly limited, but a reaction is carried out under cooling, at room temperature of under warming .
- the thus obtained compound (XXII) can be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography.
- step AA compound (Id) which is encompassed within compound (I) , or a salt thereof is prepared by reacting compound (XXII) or a reactive derivative at a carboxyl group thereof and a salt thereof with the amino compound R la R lb NH or a reactive derivative at an amino group thereof or a salt thereof.
- Step ZZ can be carried out similar to step G in Scheme 5 to prepare compound (Id) which is encompassed within compound (I) .
- Step AB can be carried out similar to step T in Scheme 14 to prepare compound (XXIV) or a salt thereof.
- Compound (XXIII) or a salt thereof can be prepared from amino derivatives corresponded to compound (XXIII) .
- Step AC can be carried out similar to step I in the Scheme 7 to prepare compound (XXIa) , which is encompassed within compound (XXI), or a salt thereof. (Method E) Scheme 20
- Step AD can be carried out similar to step C, D, and E in the Schemes 2 to 4 to prepare compound (le) which is encompassed within compound (I) .
- Compound (XXV) or a salt thereof can be prepared by the procedures described in Methods A, B and Scheme 21. Scheme 21
- Step AE can be carried out similar to step P in Scheme 11 to prepare compound (XXVa) , which is encompassed within compound (XXV) .
- Compound (XXVI) or a salt thereof can be prepared by the procedures in Schemes 22-25 described below.
- Step AF can be carried out similar to step A in Scheme 1 to prepare compound (XXVIII) or a salt thereof.
- Compound (XXVII) or a salt thereof can be prepared by the procedures described in step 0 in Scheme 11.
- Step AG can be carried out similar to step B in Scheme 1 to prepare compound (XXVIa) , which is encompassed within compound (XXVI), or a salt thereof.
- Scheme 23
- R le is an optionally substituted aryl or an optionally substituted heteroaryl, and each of the other symbols has a meaning defined above.
- a palladium catalyst may for example be bis (triphenylphosphine) palladium(II) dichloride, tris (dibenzylidineacetone) dipalladium (0) , trans- dichlorobis (tri-o-tolylphosphine) palladium, palladium (II) trifluoroacetate and palladium(II) acetate, preferably tris (dibenzylidineacetone) dipalladium (0) .
- a phosphine ligand may for example be 2, 2' -bis (diphenylphosphino) -1, 1' - binaphtyl, 2- (di-tert-butylphosphino) biphenyl, 2- (dicyclohexylphosphino) biphenyl, 2- (dicyclohexylphosphino) -
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide, sodium ethoxide, sodium tert-butoxide and potassium tert-butoxide, etc., an amine such as trimethylamine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc.
- an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc.
- an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc.
- step AH-2 1.0 to 5 moles, preferably 1.1 to 2.0 moles of R le L 1 , 0.01 to 0.5 moles, preferably 0.05 to 0.2 moles of a palladium catalyst, 0.01 to 0.5 moles, preferably 0.02 to 0.2 moles of a phosphine ligand and 1.0 to 5.0 moles, preferably 1.2 to 3 moles of a base are employed per 1 mole of an amino compound or a salt thereof.
- solvent having no adverse effect on the reaction examples include ethers such as dioxane, tetrahydrofuran and 1, 2-dimethoxyethane, aromatic hydrocarbons such as benzene, toluene and xylene, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- ethers such as dioxane, tetrahydrofuran and 1, 2-dimethoxyethane
- aromatic hydrocarbons such as benzene, toluene and xylene
- halogenated hydrocarbons such as chloroform and dichloromethane
- nitriles such as acetonitrile
- amides such as N,N-dimethylformamide and
- reaction temperature may vary depending on compound (Xlla) or a salt thereof employed as well as other reaction conditions, it is 0 to 250 °C, preferably 50 to 150 °C.
- the reaction time is 5 minutes to 120 hours, preferably 1 hour to 48 hours.
- compound (XXVIb) or a salt thereof can be prepared via compound (XXIX) .
- step Al compound (XXIX) can be prepared by the similar procedure described in step N in Scheme 10 or reacting compound (XXVIII) with an alkyl nitrite and a metal halide, etc.
- step Al 1.0 to 5 moles, preferably 1.0 to 2.0 moles of an alkyl nitrite, 0.5 to 3 moles, preferably 0.5 to 2 moles of a metal halide.
- solvent having no adverse effect on the reaction include ethers such as dioxane, tetrahydrofuran and 1, 2-dimethoxyethane, aromatic hydrocarbons such as benzene, toluene and xylene, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide, These solvents may be used by mixing at an appropriate ratio. While the reaction temperature may vary depending on compound (XXVIII) or a salt thereof employed as well as other reaction conditions, it is -10 to 200 °C, preferably
- Step AJ can be carried out similar to step AH-2 to prepare compound (XXX) by reacting with R le NH 2 or a salt thereof.
- Step AK can be carried out similar to step B in Scheme
- an oxidation agent is used and a base or an acid may be used.
- An oxidation agent may for example be potassium permanganate, potassium periodate, sodium periodate, sodium dichromate, potassium dichromate, osmium tetroxide, ruthenium tetroxide, oxygen, ozone, hydrogen peroxide, organic peroxide such as 3-chloroperoxybenzoic acid and peroxyacetic acid, etc., preferably ozone. These reagents may be used by mixing at an appropriate ratio.
- a base may for example be an alkaline metal hydroxide such as sodium hydroxide and potassium hydroxide, etc., an alkaline metal hydrogen carbonate such as sodium hydrogen carbonate and potassium hydrogen carbonate, etc., an alkaline metal carbonate such as sodium carbonate and potassium carbonate, etc., a cesium salt such as cesium carbonate, etc., an alkaline metal hydride such as sodium hydride and potassium hydride, etc., sodium amide, an alkoxide such as sodium methoxide and sodium ethoxide, etc., an amine such as trimethylamine, triethylamine and diisopropylethylamine, etc., a cyclic amine such as pyridine, etc.
- An acid may for example be an inorganic acid such as hydrochloric acid, sulfuric acid and nitric acid, etc., and an ordinary organic acid such as formic acid, acetic acid, trifluoroacetic acid and methanesulfonic acid, etc. as well as a Lewis acid.
- an inorganic acid such as hydrochloric acid, sulfuric acid and nitric acid, etc.
- an ordinary organic acid such as formic acid, acetic acid, trifluoroacetic acid and methanesulfonic acid, etc. as well as a Lewis acid.
- 1 to 10 moles, preferably 1 to 3 moles of the oxidative agent and 0.1 to 10 moles, preferably 0.3 to 2 moles of the base per 1 mole of compound (XXVIII) or a salt thereof are used.
- solvent having no adverse effect on the reaction examples include alcohols such as methanol and ethanol, ethers such as diethyl ether, dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as ethyl acetate, halogenated hydrocarbons such as chloroform and dichloromethane, nitriles such as acetonitrile, amides, such as N,N-dimethylformamide and N,N- dimethylacetamide, and sulfoxides such as dimethylsulfoxide. These solvents may be used by mixing at an appropriate ratio.
- reaction temperature may vary depending on compound (XXVIII) or a salt thereof employed as well as other reaction conditions, it is -100 to 200 °C, preferably -100 to 100 °C.
- the reaction time is 1 minute to 48 hours, preferably 1 minute to 24 hours.
- the thus obtained oxidant may be isolated and purified by the known isolating and purifying methods, for example, concentration, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, transfer dissolution and chromatography. In a reductive alkylation step, the similar manner described in step B-1 in Scheme 1 is used.
- Compound (I) obtained by any method described above, as a free form may be converted in accordance with a standard procedure for example into a salt with an inorganic acid (for example, hydrochloric acid, sulfuric acid and hydrobromic acid, etc.), an organic acid (for example, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, oxalic acid, fumaric acid, maleic acid and tartaric acid, etc.), an inorganic base (for example, alkaline metal such as sodium and potassium, etc., .alkaline earth metal such as calcium and magnesium, etc., aluminum and ammonium, etc.) or an organic base (for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine and N,N' -dibenzylethylenediamine, etc.), while compound (I) obtained as a salt may be converted into a free
- a starting compound for compound (I) according to the invention may be in a form of a salt, including a salt with an inorganic acid (for example, hydrochloric acid, phosphoric acid, hydrobromic acid and sulfuric acid, etc.) and a salt with an organic acid (for example, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid and benzenesulfonic acid, etc.).
- an inorganic acid for example, hydrochloric acid, phosphoric acid, hydrobromic acid and sulfuric acid, etc.
- an organic acid for example, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid and benzenes
- a salt with an inorganic base for example, an alkaline metal or an alkaline earth metal such as sodium, potassium, calcium and magnesium, ammonia, etc.
- an organic base for example, tri-C ⁇ - 3 alkyla ine such as triethylamine, etc.
- a starting compound when carries as a substituent an amino group, an amide group, a urea group, a carboxyl group or a hydroxyl group, then such group may be derivatized with a protective group employed ordinarily in peptide chemistry, which is cleaved after a reaction if desired to yield an intended compound.
- a protective group for an amino group, an amide group and a urea group may for, example be, an optionally substituted C ⁇ - 6 alkylcarbonyl (for example.
- phenylcarbonyl formyl, methylcarbonyl and ethylcarbonyl, etc.
- phenylcarbonyl a C ⁇ - 6 alkyloxycarbonyl (for example, methoxycarbonyl, ethoxycarbonyl and tert-butylcarbonyl, etc.), phenyloxycarbonyl (for example, benzoxycarbonyl) , C 7 - ⁇ o aralkylcarbonyl (for example, benzyloxycarbonyl) , C_ ⁇ 0 aralkyl (for example, benzyl and 4-methoxybenzyl, etc.), trityl, phthaloyl, etc.
- a substituent on each of the groups listed above may be a halogen atom (for example, fluorine, chlorine, bromine and iodine, etc.), a C ⁇ _ 6 alkylcarbonyl (for example, methylcarbonyl, ethylcarbonyl and butylcarbonyl, etc.) and a nitro group, which may occur 1 to about 3 times.
- a protective group for a carboxyl group may for example be an optionally substituted C ⁇ _ 6 alkyl (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, etc.), phenyl, trityl and silyl, etc.
- a substituent on each of the groups listed above may be a halogen atom (for example, fluorine, chlorine, bromine and iodine, etc.), a C ⁇ - 6 alkylcarbonyl (for example, formyl, methylcarbonyl, ethylcarbonyl and butylcarbonyl, etc.) and a nitro group, which may occur 1 to about 3 times.
- a protective group for a hydroxyl group may.
- C ⁇ _ 6 alkyl for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and tert-butyl, etc.
- phenyl for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and tert-butyl, etc.
- phenyl for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and tert-butyl, etc.
- phenyl for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and tert-butyl, etc.
- phenyl for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and tert-butyl, etc.
- phenyl for example
- a substituent on each of the groups listed above may be a halogen atom (for example, fluorine, chlorine, bromine and iodine, etc.), a C ⁇ _ 6 alkyl, phenyl, a C 7 - ⁇ o aralkyl, nitro, etc., which may occur 1 to about 4 times.
- a method for cleaving a protective group is a method known per se or an analogous method, such as a treatment for example with an acid, a base, a reduction, UV light, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate, etc.
- the pharmaceutical composition containing compound (I) or (la) of the present invention is expected to be useful in the treatment and prevention of diseases, in which CRF is involved, such as great depression, postpartum depression, suppression symptom, mania, anxiety, generalized anxiety disorder, panic disorder, phobia, obsessive-compulsive disorder, post psychic trauma stress disorder, Tourette' s syndrome, autism, passion disorder, adjustment disorder, dysthymic disorder, sleep disorder, insomnia, bipolar disorder, circulatory disease, neurosis, schizophrenia, digestive ulcer, irritable bowl syndrome, ulcerative colitis, Crohn' s disease, diarrhea, constipation, postoperative ileus, gastrointestine dysfunction and nervous vomiting associated with stress, Alzheimer's disease, Alzheimer's type senile dementia, nervous degenerated disease such as Parkinson' s disease and Huntington' s disease, multi-infarct dementia, senile dementia, nervous orexia inactivity, hyperphagia and other ingestion disorder, obesity, diabetes, alcohol dependency, pharmacophinia, drug withdrawal, migraine, stress
- Compound (I) or (la) of the present invention can be formulated with a pharmaceutically acceptable carrier and can be orally or parenterally administered as solid formulations such as tablets, capsules, granules, powders, or the like; or liquid formulations such as syrups, injections, or the like. Also, there can be prepared formulations for transdermal administration such as patchings, cataplasms, ointments (including creams), plasters, tapes, lotions, liquids and solutions, suspensions, emulsions, sprays, and the like.
- a variety of organic or inorganic carrier substances which have been conventionally employed as formulation materials, is used and compounded as a bulking agent, a lubricant, a binding agent, and a disintegrator in solid formulations; a vehicle, a solubilizing agent, a suspending agent, an isotonicity agent, a buffering agent, and an analgesic in liquid formulations.
- formulation excipients such as a preservative, an antioxidant, a stabilizer, a coloring agent, a sweetening agent, and the like can be used.
- Preferred examples of the bulking agent include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light anhydrous silicic acid, and the like.
- Preferred examples of the lubricant include magnesium stearate, potassium stearate, talc, colloidal silica, and the like.
- Preferred examples of the binding agent include crystalline cellulose, ⁇ -starch, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, and the like.
- Preferred examples of the disintegrator include starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and the like.
- Preferred examples of the vehicle include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and the like. If necessary, for the purpose of taste masking, enteric coating, or prolonged action, oral formulations can be prepared by coating by a per se known method.
- this coating agent examples include hydroxypropylmethyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, polyoxyethylene glycol, Tween 80, Pluronic F68 [polyoxyethylene (160) polyoxypropylene (30) glycol], cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxymethyl cellulose acetate phthalate, Eudragit (manufactured by Rohm Company, methacrylic acid- acrylic acid copolymer) , and the like.
- Preferred examples of the solubilizing agent include polyethylene glycol, propylene glycol, benzyl benzoate, ethanol, trisamiomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, and the like.
- Preferred examples of the suspending agent include surface active agents such as stearyltriethanolamine, sodium lauryl sulfate, laurylammopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glycerin monostearate, and the like; hydrophilic, high molecular substances such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and the like; and so on..
- Preferred examples of the isotonicity agent include sodium chloride, glycerin, D- mannitol, and the like.
- Preferred examples of the buffering agent include buffer solutions of a phosphate, an acetate, a carbonate, a citrate, or the like.
- Preferable examples of the analgesic include benzyl alcohol and the like.
- Preferred examples of the preservative include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, and the like.
- Preferred examples of the antioxidant include sulfites, ascorbic acid, and the like.
- Example 1 ⁇ -Mesityl-N 7 , N 7 -dipropyl-l , 3-benzothiazole-2, 7-diamine :
- N 2 -Mesityl-7-nitro-l , 3-benzothiazol-2-amine A mixture of 2.25 g (12.5 mmol) of 3- nitrophenylisothiocyanate and 1.4 mL (10 mmol) of mesityl amine in 10 mL of methanol was stirred at room temperature for 2 h. The resulting precipitate was collected by filtration and dried to give a quantitative yield of l-(3- nitrophenyl) -3- (mesityl) thiourea. To 1.8 g (5.7 mmol) of the thiourea thus prepared slurried in 20 mL of CC1 was added 0.35 mL (6.9 mmol) of bromine.
- N 2 -Mesityl-1 , 3-benzothiazole-2, 7-diamine To a solution of 1.8 g (5.7 mmol) of N 2 -mesityl-7- nitro-1, 3-benzothiazol-2-amine in 7.2 mL of glacial acetic acid and 25 mL of ethanol was added 1.8 g (32 mmol) of iron powder. The resulting solution was heated at reflux for 18 h before being cooled to room temperature. The slurry was filtered and the filtrate was concentrated to a brown solid.
- the reaction was cooled to room temperature and 0.15 g (4 mmol) of sodium borohydride was added.
- the reaction was heated to 80 °C for 1 h and cooled to room temperature.
- the mixture was diluted with dichloromethane and was washed successively with water and brine before being dried over sodium sulfate.
- the solution was filtered, concentrated in vacuo and the resulting crude oil was purified by flash chromatography eluting with a 80% hexanes/ethyl acetate mixture to give 0.41 g (38%) of the title compound as a colorless oil.
- N 2 -Diphenylmethylene-N 4 ,i ⁇ 4 -dipropylpyridine-2 , 4-diamine A mixture of 0.52 g (2.4 mmol) of 2-chloro-.N*,tf 4 - dipropylpyridin-4-amine, 0.076 g (0.12 mmol) of racemic 2, 2' -bis (diphenylphosphino) -1, 1' -binaphtyl (BINAP) , 0.33 g (3.4 mmol) of sodium tert-butoxide and 0.027 g (0.12 mmol) of palladium (II) acetate in 25 mL of toluene was treated with 0.49 mL (2.9 mmol) of benzophenone imine and heated to 85 °C for 18 h.
- N 4 ,iV 4 -Dipropylpyridine-2 , 4-diamine To 0.235 g (0.66 mmol) of I ⁇ -diphenylmethylene-N , ⁇ / 4 - dipropylpyridine-2, 4-diamine in 9 mL of methanol was added 0.13 g (1.6 mmol) of sodium acetate followed by 0.082 g (1.2 mmol) of hydroxylamine hydrochloride . The resulting clear golden reaction mixture was stirred at room temperature for 45 min and concentrated in vacuo . The crude solids were slurried in dichloromethane, filtered and the filtrate was concentrated. The resulting oil was purified by flash chromatography eluting with a 13% to 20% methanol/dichloromethane gradient containing 2% triethylamine to give 0.106 g (83%) of the title compound as a white solid.
- N,I ⁇ 7-dimethylformamide (DMF) was added dropwise 0.15 mL
- N 2 - (1-Phenylethyl) -1, 3-benzothiazole-2, 7-diamine (C) To 0.165 g (0.55 mmol) of 7-nitro-N 2 - (1-phenylethyl) - 1, 3-benzothiazol-2-amine in 10 mL of DMF was added 0.62 g (2.8 mmol) of stannous chloride dihydrate. The reaction was heated to 80 °C for 48 h and neutralized with saturated sodium bicarbonate. The mixture was filtered through celite and extracted with ethyl acetate.
- N 2 - (1-Phenylethyl) -N 7 , N 7 -dipropyl-l , 3-benzothiazole-2, 7- diamine (D) To 0.016 g (0.059 mmol) of IV 2 - (1-phenylethyl) -1, 3- benzothiazole-2, 7-diamine and 21 ⁇ L (0.30 mmol) of propionaldehyde in 2 mL of dichloroethane was added one drop of glacial acetic acid and 0.038 g (0.18 mmol) of sodium triacetoxyborohydride. The mixture was heated to 50 °C for 3 h and concentrated in vacuo .
- 2-Morpholin-4-yl-7-nitro-l, 3-benzothiazole To 0.200 g (0.77 mmol) of 2-bromo-7-nitro-l, 3- benzothiazole in 2 mL of DMF was added 0.21 g (1.5 mmol) of potassium carbonate and 81 ⁇ L (0.93 mmol) of morpholine.
- 2-Morpholin-4-yl-I ⁇ J,-V-dipropyl-l, 3-benzothiazol-7-amine To 0.022 g (0.094 mmol) of 2-morpholin-4-yl-l, 3- benzothiazol-7-amine and 40 ⁇ L (0.56 mmol) of propionaldehyde in 2 mL of dichloroethane was added one drop of glacial acetic acid and 0.064 g (0.30 mmol) of sodium triacetoxyborohydride. The mixture was heated to 50 °C for 5 h and concentrated in vacuo .
- N- (7- (Dipropylamino) -1, 3-benzothiazol-2-yl) -2, 4, 6- trimethylbenzamide To 0.118 g (0.379 mmol) of N- (7-amino-l, 3- benzothiazol-2-yl) -2, 4, 6-trimethylbenzamide and 0.14 mL (1.9 mmol) of propionaldehyde in 5 mL of dichloroethane was added one drop of glacial acetic acid and 0.24 g (1.1 mmol) of sodium triacetoxyborohydride. The mixture was heated to 50 °C for 3 h and an additional 0.14 L of propionaldehyde was added.
- A Methyl 2-mesitylamino-7-nitro-l, 3-benzothiazole-5- carboxylate
- Methyl 2-mesitylamino-5-nitro-l, 3- benzothiazole-7-carboxylate B
- the aqueous solution was extracted with dichloromethane.
- 2-Amino-6-nitrophenol A suspension of 2, 6-dinitrophenol 5.0 g (27 mmol), ammonium hydroxide (3 ml) and ammonium chloridel4.3 g (270 mmol) in 30 ml of water was heated to 70°C. A solution of sodium sulfide nonahydrate (24.19 g, 100 mmol) in water was added and the resulting mixture stirred at 70°C for 2h. The reaction was cooled to room temperature, acidified (pH
- N-Mesityl-7-nitro-l, 3-benzoxazol-2-amine To a solution containing 0.06 g (0.18 mmol) of l-(2- hydroxy-3-nitrophenyl) -3-mesitylthiourea in acetonitrile was added O.lOg (0.36 mmol) of mercury (II) chloride, and the mixture was then stirred for lh . The reaction mixture was diluted with ethyl acetate (2 ml) and filtered through a prepacked celite column. The filtrate was concentrated under reduced pressure and the residue purified via Biotage chromatography eluting with 20% ethyl acetate/ dichloromethane to afford 0.047 g (90 %) of product.
- N 2 -Methylbenzene-1 , 2, 3-triamine To a flask was added 0.30 g (1.5 mmol) of 2,6-dinitro- N-methylaniline and 40 ml of methanol. The flask was purged with nitrogen followed by the addition of 0.03 g of 10% palladium on carbon. The flask was evacuated and pressurized to 2-3 psig hydrogen and stirred for lh. After completion as determined by HPLC, the reaction was filtered through GF/F filter paper. The filtrate was evaporated to give 0.2g (95%) of product. MS Calcd.: 137; Found: 138 (M+H).
- N 2 -Mesityl-l-methyl-lH-benzimidazole-2 , 7-diamine To a solution containing 0.25 g (0.79mmol) of l-(3- amino-2-methylaminophenyl) -3-mesitylthiourea in acetonitrile was added 0.52g (1.6 mmol) of mercury (II) chloride, and the mixture stirred for lh. The reaction mixture was diluted with ethyl acetate (2ml) and filtered through a prepacked celite column.
- the mixture was stirred at 50 °C for 18 h and an additional 0.68 mL of benzaldehyde, 10 drops of glacial acetic acid and 0.63 g of sodium cyanoborohydride was added. This mixture was heated for an additional 24 h before adding an additional 0.68 mL of benzaldehyde, 10 drops of glacial acetic acid and 0.63 g of sodium cyanoborohydride. The reaction was cooled to room temperature and the volatiles were removed in vacuo .
- N 7 -Benzyl-2-chloro ⁇ l-methyl-N 7 -propyl-l.H-benzimidazol-7- amine A solution of 0.65 g (2.2 mmol) of 7- benzyl (propyl) amino-l-methyl-1, 3-dihydro-2H-benzimidazol-2- one in 10 mL of phosphorous oxychloride was heated to 100 °C. After stirring for 24 h, the mixture was concentrated in vacuo and quenched with saturated sodium bicarbonate.
- N 7 -Benzyl-.N 2 -mesityl-l-methyl-N 7 -propyl-l.H-benzimidazole- 2, 7-diamine A solution of 0.56 g (1.8 mmol) of N 7 -benzyl-2-chloro- l-methyl-N 7 -propyl-li ⁇ -benzimidazol-7-amine in 0.75 mL (5.4 mmol) of mesityl amine was heated to 130 °C. After stirring for 24 h, the mixture was dissolved in ethyl acetate and washed with saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered and concentrated to give a tan solid.
- N 2 -Mesityl-l-methyl-N 7 -propyl-li ⁇ -benzimidazole-2 , 7-diamine To a solution of 0.50 g (1.2 mmol) of N 7 -benzyl-N 2 - mesityl-l-methyl-N 7 -propyl-lu-benzimidazole-2 , 7-diamine in 30 mL of methanol was added 0.43 g (10 mol% Pd) of 20% Pearlman' s catalyst (50% wet). The reaction was kept under a hydrogen atmosphere via a balloon and stirred at room temperature for 48 h. The catalyst was removed via filtration and the filtrate was concentrated in vacuo .
- N 7 -Cyclopropylmethyl-N 2 -mesityl-l-methyl-lV 7 -propyl-l- ⁇ - benzimidazole-2 , 7-diamine To 0 . 041 g ( 0. 13 mmol) of N 2 -mesityl-l-methyl-N 7 - propyl-lH-benzimidazole-2, 7-diamine in 2 mL of methanol was added 95 ⁇ L (1.3 mmol) of cyclopropane carboxaldehyde, 200 ⁇ L of glacial acetic acid and 0.032 g (0.51 mmol) of sodium cyanoborohydride. The mixture was stirred at room temperature for 24 h.
- Imidazo [1, 2-a]pyridin-5-amine 2, 6-diaminopyridine (5.0g, 46 mmol) and chloroacetaldehyde (50% wt. soln in water, 6.4 mL, 50 mmol) were dissolved in absolute EtOH (120 mL) . The solution was heated at 75 °C for 1 hour. The mixture was cooled and concentrated via rotavap. The residue was taken up in saturated NaHC0 3 and EtOAc. The solution was extracted with EtOAc (3 times), dried over magnesium sulfate, and concentrated to give a brown solid. 4.85g isolated (80% yield) .
- N,IV-Dipropylimidazo [1, 2-a] pyridin-5-amine Imidazo [1, 2-a] pyridin-5-amine (4.85g, 36 mmol) was dissolved in DMF (72 mL) . Sodium hydride (60% in mineral oil, 5.8g, 146 mmol) was added carefully. The mixture stirred for 0.5 hr. at room temperature. 1-Bromopropane
- the crude solid was mixed with water and made basic with saturated potassium carbonate. The mixture was partioned with ethyl acetate and separated. The organic layer was washed with brine, dried over sodium sulfate, filtered, concentrated onto silica gel and purified by flash chromatography eluting with a 75% hexanes/ethyl acetate mixture to give impure title compound. The impure material was slurried in hexanes and 0.065 g (20%) of the title compound was collected as a white solid.
- N 7 -Butyl-N 2 -mesityl-N 7 - (4-methoxyphenyl) -1-methyl-lH- benzimidazole-2, 7-diamine A solution of 0.018 g (0.05 mmol) of N-butyl-2-chloro- N- (methoxyphenyl) -l-methyl-lH-benzimidazol-7-amine in 0.10 mL (0.73 mmol) of mesityl amine was heated to 130 °C.
- Example 114-117 shown in Table 7 were prepared in a similar manner to that described previously in Example 1.
- the crude, ozonide was transferred directly to a mixture of 7-amino-l- methyl-1, 3-dihydro-222-benzimidazol-2-one (0.5 g, 3.07 mmol) and 10% palladium on carbon (0.05 g, Degussa type; 50% wet) .
- the flask was fitted with a balloon of hydrogen and allowed to stir for 12 h.
- the reaction was filtered through GF/F paper and the filtrate concentrated under reduced pressure.
- the residue was purified by column chromatography eluting with a 10% acetone/hexanes mixture to afford 597 mg (75%) of the title compound.
- N- (4-Bromo-2-methoxy-6-methylphenyl) -7- (2-ethyl-l- piperidinyl) -l-methyl-122-benzimidazol-2-amine A mixture of 2-chloro-7- (2-ethyl-l-piperidinyl) -1- methyl-122-benzimidazole (100 mg, 0.36 mmol) and 4-bromo-2- methoxy-6-methylaniline (390 mg, 1.8 mmol) was heated at 110 °C for 12 h. The mixture was dissolved in ethyl acetate and washed with saturated sodium bicarbonate in water, dried over magnesium sulfate and concentrated under vacuum.
- N 3 -Methylpyridine-3 4-diamine
- 4-diamine in 150 mL of methanol was added 2 mL of Raney nickel (50% slurry in water) .
- the reaction mixture was purged with hydrogen and then stirred under balloon pressure hydrogen overnight.
- the catalyst was removed by filtration through GFF paper and the filtrate was concentrated in vacuo to a pink residue that solidified under high vacuum to give 2.90 g (100%) of the title compound.
- Example 197 A compound of Example 197, shown in the Table 17, was prepared in a manner similar to that described in Example 193. Table 17
- Example 198 A compound of Example 198, shown in the Table 18, was prepared in a manner similar to that described in Example 194. Table 18
- Methyl 2- [ (4-bromo-2-methoxy-6-methylphenyl) amino] -1- methyl-lI2-benzimidazole-7-carboxylate A mixture of 1.50 g (6.68 mmol) of methyl 2-chloro-l- methyl-122-benzimidazole-7-carboxylate and 2.89 g (13.4 mmol) of 4-bromo-2-methoxy-6-methylphenylamine was heated at 100 °C for five days. The cooled reaction was dissolved in dichloromethane and washed with saturated aqueous sodium bicarbonate, water and brine. The organics were dried over sodium sulfate, filtered, and concentrated in vacuo .
- a test compound 100 nM was incubated with 1 ⁇ g of human CRF receptor expressing CHO cellular membrane fraction and 50 pM of 125 1- CRF in a binding assay buffer (50 mM Tris-HCl, 5 mM EDTA, 10 mM MgCl 2 , 0.05% CHAPS, 0.1% BSA, 0.5 mM PMSF, 0.1 g/ml pepstatin, 20 ⁇ g/ml leupeptin, pH 7.5).
- a binding assay buffer 50 mM Tris-HCl, 5 mM EDTA, 10 mM MgCl 2 , 0.05% CHAPS, 0.1% BSA, 0.5 mM PMSF, 0.1 g/ml pepstatin, 20 ⁇ g/ml leupeptin, pH 7.5.
- 0.1 ⁇ M unlabelled human Urocortin was incubated with 1 ⁇ g of human CRF receptor expressing CHO cellular membrane fraction and 50 pM of 125 I-CRF in a binding assay buffer. After a binding reaction was carried out at room temperature for 1 hour, the membrane was entrapped on a glass filter (UniFilter plate GF-C/Perkin Elmer) by suction filtration using a cell harvester (Perkin Elmer) , and washed with ice-cooled 50 mM Tris-HCl (pH 7.5).
- a glass filter UniFilter plate GF-C/Perkin Elmer
- CRF antagonistic activity was obtained by measuring inhibition of Adenylate Cyclase activity induced by CRF. Measurement of intracellular cyclic AMP (cAMP) concentration was carried out using Alpha Screen Reagent (Perkin Elmer) according to the method described in the protocol attached to the reagent. Specifically, a human CRF receptor expressing CHO cell was inoculated on a 96- well plate at 40000 cells/well, cultured for 24 hours, the culture medium was sucked, and 1 ⁇ M of test compound and 100 ⁇ l of assay buffer (20 mM HEPES, Hanks' Balanced Salt Solution, 0.1% BSA, 100 ⁇ M IBMX, pH 7.2) containing 1 nM of human CRF were added.
- assay buffer 20 mM HEPES, Hanks' Balanced Salt Solution, 0.1% BSA, 100 ⁇ M IBMX, pH 7.2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/577,334 US7714009B2 (en) | 2003-10-31 | 2004-10-27 | Nitrogen-containing fused heterocyclic compounds |
JP2006538217A JP4842829B2 (en) | 2003-10-31 | 2004-10-27 | Nitrogen-containing fused heterocyclic compounds |
CA002543707A CA2543707A1 (en) | 2003-10-31 | 2004-10-27 | Nitrogen-containing fused heterocyclic compounds |
EP04810065A EP1677791A4 (en) | 2003-10-31 | 2004-10-27 | Nitrogen-containing fused heterocyclic compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51616403P | 2003-10-31 | 2003-10-31 | |
US60/516,164 | 2003-10-31 | ||
US56051804P | 2004-04-08 | 2004-04-08 | |
US60/560,518 | 2004-04-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005044793A2 true WO2005044793A2 (en) | 2005-05-19 |
WO2005044793A3 WO2005044793A3 (en) | 2006-03-30 |
Family
ID=34576771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/035648 WO2005044793A2 (en) | 2003-10-31 | 2004-10-27 | Nitrogen-containing fused heterocyclic compounds |
Country Status (5)
Country | Link |
---|---|
US (1) | US7714009B2 (en) |
EP (1) | EP1677791A4 (en) |
JP (1) | JP4842829B2 (en) |
CA (1) | CA2543707A1 (en) |
WO (1) | WO2005044793A2 (en) |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1568699A1 (en) * | 2002-12-04 | 2005-08-31 | Eisai Co., Ltd. | 1,3-dihydroimidazole fused-ring compound |
WO2006078907A1 (en) * | 2005-01-20 | 2006-07-27 | Amgen Inc. | 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments |
WO2007009774A1 (en) * | 2005-07-21 | 2007-01-25 | Novartis Ag | Benzimidazole derivatives for treatment of inflammatory diseases |
WO2007041379A1 (en) * | 2005-09-30 | 2007-04-12 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007069565A1 (en) | 2005-12-12 | 2007-06-21 | Ono Pharmaceutical Co., Ltd. | Bicyclic heterocyclic compound |
FR2903105A1 (en) * | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | 2-BENZOYL-IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2008051533A2 (en) | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
WO2008082003A1 (en) * | 2006-12-29 | 2008-07-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds having crf antagonistic activity |
WO2009138176A1 (en) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines as gsk3beta-inhibitors |
WO2010032461A1 (en) * | 2008-09-17 | 2010-03-25 | 武田薬品工業株式会社 | Nitrogen-containing fused ring compound |
US7704989B2 (en) | 2006-07-03 | 2010-04-27 | Sanofi-Aventis | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics |
WO2010084050A2 (en) | 2009-01-13 | 2010-07-29 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
EP2305652A2 (en) | 2005-12-08 | 2011-04-06 | Novartis AG | Trisubstituted quinazolinone derivatives as vanilloid antagonists |
US7960561B2 (en) | 2005-06-21 | 2011-06-14 | Neurosearch A/S | 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
CN102153538A (en) * | 2010-02-11 | 2011-08-17 | 山东轩竹医药科技有限公司 | Benzocyclodirivative |
US8163935B2 (en) | 2005-04-27 | 2012-04-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
US8207350B2 (en) | 2006-02-15 | 2012-06-26 | Abbott Laboratories | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
WO2012164473A1 (en) | 2011-05-27 | 2012-12-06 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8394969B2 (en) | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
US8563746B2 (en) | 2008-10-29 | 2013-10-22 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2013164790A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
US8598190B2 (en) | 2008-09-25 | 2013-12-03 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US8674113B2 (en) | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8748627B2 (en) | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8921405B2 (en) | 2009-03-05 | 2014-12-30 | Orexo Ab | Compounds |
WO2016198322A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
WO2017009325A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US9957235B2 (en) | 2014-02-11 | 2018-05-01 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as mIDH1 inhibitors |
US9994546B2 (en) | 2014-02-13 | 2018-06-12 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US10137110B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors |
US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
US10300051B2 (en) | 2014-02-13 | 2019-05-28 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10329255B2 (en) | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
CN110156712A (en) * | 2019-04-25 | 2019-08-23 | 邵玉田 | It is a kind of to utilize aromatic nitration by-product synthesis benzoxazoles class compound and application |
US10513493B2 (en) | 2014-02-13 | 2019-12-24 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
US11773110B2 (en) | 2010-11-19 | 2023-10-03 | Ligand Pharmaceuticals Incorporated | Heterocycle amines and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
CN108970632A (en) * | 2018-08-14 | 2018-12-11 | 浙江辰阳化工有限公司 | A kind of load type bimetal catalyst and preparation method thereof efficiently synthesizing DBE |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH653021A5 (en) | 1981-04-24 | 1985-12-13 | Delalande Sa | PIPERIDINO, PIPERAZINO AND HOMOPIPERAZINO DERIVATIVES, N-SUBSTITUTED BY AN AROMATIC HETEROCYCLIC GROUP, THEIR PREPARATION METHOD AND THERAPEUTIC COMPOSITION CONTAINING THEM. |
NZ209876A (en) | 1983-10-17 | 1988-03-30 | Duphar Int Res | Piperazines and pharmaceutical compositions |
DE4241658A1 (en) | 1992-12-04 | 1994-06-09 | Schering Ag | Substd. 2-thiobenzthiazole derivs. - selective herbicides esp. suitable for use in beet, cotton, soya and cereal crops |
NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
US6077812A (en) | 1997-02-26 | 2000-06-20 | Fmc Corporation | Cycloimido-substituted benzofused heterocyclic herbicides |
US6281237B1 (en) * | 1999-04-02 | 2001-08-28 | Neurogen Corporation | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives |
JP2003528802A (en) * | 1999-04-02 | 2003-09-30 | ニューロゲン コーポレイション | N-benzimidazolylmethyl- and N-indolylmethyl-benzamides and their use as CRF modulators |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
ES2238437T3 (en) | 2000-04-28 | 2005-09-01 | Acadia Pharmaceuticals Inc. | MUSCARINIC AGONISTS. |
JP2004504300A (en) | 2000-07-18 | 2004-02-12 | ビーエーエスエフ アクチェンゲゼルシャフト | 1-aryl-4-haloalkyl-2- [1H] pyridones |
TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
US6599901B1 (en) | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
BR0214455A (en) | 2001-11-27 | 2004-11-03 | Hoffmann La Roche | Benzothiazole Derivatives |
US6624163B2 (en) | 2001-11-29 | 2003-09-23 | Hoffman-La Roche Inc. | Benzothiazole derivatives |
US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
US6713499B2 (en) | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
US7087761B2 (en) * | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
FR2851563B1 (en) * | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
-
2004
- 2004-10-27 JP JP2006538217A patent/JP4842829B2/en not_active Expired - Fee Related
- 2004-10-27 CA CA002543707A patent/CA2543707A1/en not_active Abandoned
- 2004-10-27 US US10/577,334 patent/US7714009B2/en not_active Expired - Fee Related
- 2004-10-27 WO PCT/US2004/035648 patent/WO2005044793A2/en active Application Filing
- 2004-10-27 EP EP04810065A patent/EP1677791A4/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of EP1677791A4 * |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1568699A1 (en) * | 2002-12-04 | 2005-08-31 | Eisai Co., Ltd. | 1,3-dihydroimidazole fused-ring compound |
US7524847B2 (en) | 2002-12-04 | 2009-04-28 | Eisai R&D Management Co., Ltd. | Fused 1,3-dihydro-imidazole ring compounds |
EP1568699A4 (en) * | 2002-12-04 | 2007-08-15 | Eisai R&D Man Co Ltd | 1,3-dihydroimidazole fused-ring compound |
US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
WO2006078907A1 (en) * | 2005-01-20 | 2006-07-27 | Amgen Inc. | 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments |
US8163935B2 (en) | 2005-04-27 | 2012-04-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
US7960561B2 (en) | 2005-06-21 | 2011-06-14 | Neurosearch A/S | 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
WO2007009774A1 (en) * | 2005-07-21 | 2007-01-25 | Novartis Ag | Benzimidazole derivatives for treatment of inflammatory diseases |
WO2007041379A1 (en) * | 2005-09-30 | 2007-04-12 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
EP2305652A2 (en) | 2005-12-08 | 2011-04-06 | Novartis AG | Trisubstituted quinazolinone derivatives as vanilloid antagonists |
WO2007069565A1 (en) | 2005-12-12 | 2007-06-21 | Ono Pharmaceutical Co., Ltd. | Bicyclic heterocyclic compound |
US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8207350B2 (en) | 2006-02-15 | 2012-06-26 | Abbott Laboratories | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8748627B2 (en) | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
WO2008003854A3 (en) * | 2006-07-03 | 2008-03-06 | Sanofi Aventis | Derivatives of 2-benzoyl-imidazopyridines, preparation method thereof and use of same in therapeutics |
WO2008003854A2 (en) * | 2006-07-03 | 2008-01-10 | Sanofi-Aventis | Derivatives of 2-benzoyl-imidazopyridines, preparation method thereof and use of same in therapeutics |
FR2903105A1 (en) * | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | 2-BENZOYL-IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
US8404848B2 (en) | 2006-07-03 | 2013-03-26 | Sanofi | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics |
US7704989B2 (en) | 2006-07-03 | 2010-04-27 | Sanofi-Aventis | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics |
US7902219B2 (en) | 2006-07-03 | 2011-03-08 | Sanofi-Aventis | 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof |
EP2088861A2 (en) * | 2006-10-25 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
EP2088861A4 (en) * | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | Benzimidazole compounds |
JP2010507664A (en) * | 2006-10-25 | 2010-03-11 | 武田薬品工業株式会社 | Benzimidazole compounds |
WO2008051533A2 (en) | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
JP2010514672A (en) * | 2006-12-29 | 2010-05-06 | 武田薬品工業株式会社 | Fused heterocyclic compounds having CRF antagonist activity |
WO2008082003A1 (en) * | 2006-12-29 | 2008-07-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds having crf antagonistic activity |
US8039500B2 (en) | 2006-12-29 | 2011-10-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
DE102008023801A1 (en) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo and triazolopyrimidines, imidazo and pyrazolopyrazines and imidazotriazines |
WO2009138176A1 (en) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines as gsk3beta-inhibitors |
WO2010032461A1 (en) * | 2008-09-17 | 2010-03-25 | 武田薬品工業株式会社 | Nitrogen-containing fused ring compound |
US8703796B2 (en) | 2008-09-25 | 2014-04-22 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents |
US8598190B2 (en) | 2008-09-25 | 2013-12-03 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US9040565B2 (en) | 2008-09-25 | 2015-05-26 | Orexo Ab | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents |
US8916599B2 (en) | 2008-09-25 | 2014-12-23 | Orexo Ab | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents |
US8394969B2 (en) | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8563746B2 (en) | 2008-10-29 | 2013-10-22 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2010084050A2 (en) | 2009-01-13 | 2010-07-29 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8921405B2 (en) | 2009-03-05 | 2014-12-30 | Orexo Ab | Compounds |
WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
CN102153538A (en) * | 2010-02-11 | 2011-08-17 | 山东轩竹医药科技有限公司 | Benzocyclodirivative |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
US11773110B2 (en) | 2010-11-19 | 2023-10-03 | Ligand Pharmaceuticals Incorporated | Heterocycle amines and uses thereof |
US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8674113B2 (en) | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
WO2012164473A1 (en) | 2011-05-27 | 2012-12-06 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
WO2013164790A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
US9957235B2 (en) | 2014-02-11 | 2018-05-01 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as mIDH1 inhibitors |
US10442772B2 (en) | 2014-02-11 | 2019-10-15 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as mIDH1 inhibitors |
US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US11247992B2 (en) | 2014-02-13 | 2022-02-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10717737B2 (en) | 2014-02-13 | 2020-07-21 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10676457B2 (en) | 2014-02-13 | 2020-06-09 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10513493B2 (en) | 2014-02-13 | 2019-12-24 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9994546B2 (en) | 2014-02-13 | 2018-06-12 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10300051B2 (en) | 2014-02-13 | 2019-05-28 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10174030B2 (en) | 2014-02-13 | 2019-01-08 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10138249B2 (en) | 2014-07-10 | 2018-11-27 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US10640503B2 (en) | 2014-07-10 | 2020-05-05 | Incyte Corporation | Imidazopyridines and imidazopyrazines as LSD1 inhibitors |
US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US10125133B2 (en) | 2014-07-10 | 2018-11-13 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US10112950B2 (en) | 2014-07-10 | 2018-10-30 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US10047086B2 (en) | 2014-07-10 | 2018-08-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as LSD1 inhibitors |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US10556908B2 (en) | 2014-07-10 | 2020-02-11 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
US10137110B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US11401272B2 (en) | 2015-04-03 | 2022-08-02 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US10800779B2 (en) | 2015-04-03 | 2020-10-13 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US10370339B2 (en) | 2015-06-08 | 2019-08-06 | Bayer Pharma Aktiengesellschaft | N-Methylbenzimidazoles as mIDH1 inhibitors |
WO2016198322A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
WO2017009325A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
US10329255B2 (en) | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
US10723700B2 (en) | 2015-08-12 | 2020-07-28 | Incyte Corporation | Salts of an LSD1 inhibitor |
US11498900B2 (en) | 2015-08-12 | 2022-11-15 | Incyte Corporation | Salts of an LSD1 inhibitor |
US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
US11512064B2 (en) | 2018-08-31 | 2022-11-29 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
CN110156712A (en) * | 2019-04-25 | 2019-08-23 | 邵玉田 | It is a kind of to utilize aromatic nitration by-product synthesis benzoxazoles class compound and application |
Also Published As
Publication number | Publication date |
---|---|
WO2005044793A3 (en) | 2006-03-30 |
JP2007510646A (en) | 2007-04-26 |
EP1677791A4 (en) | 2007-08-15 |
US7714009B2 (en) | 2010-05-11 |
EP1677791A2 (en) | 2006-07-12 |
US20070135452A1 (en) | 2007-06-14 |
JP4842829B2 (en) | 2011-12-21 |
CA2543707A1 (en) | 2005-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7714009B2 (en) | Nitrogen-containing fused heterocyclic compounds | |
EP0268989B1 (en) | Imidazopyridine compounds and processes for preparation thereof | |
US8163935B2 (en) | Fused heterocyclic compounds | |
JP4790703B2 (en) | Cyclic compounds | |
EP0691960B1 (en) | Antipsychotic benzimidazole derivatives | |
KR101346823B1 (en) | Heterocyclic compounds | |
SK285432B6 (en) | Distributed bicyclic heterocycles, method of their preparation, pharmaceuticals containing them and their use | |
HU196971B (en) | Process for producing new benzimidazol derivatives and pharmaceutical compositions containing them | |
US5565469A (en) | Benzimidazoles and pharmaceutical compositions containing them | |
SK1942001A3 (en) | 1h-imidazopyridine derivatives | |
KR20030019555A (en) | Propane-1,3-Dione Derivatives | |
JPH08269059A (en) | Novel pyrido(3,2-e)pyrazinone and its production,antathmaticand antiallergic drug containing it,and production of the drug | |
US4782055A (en) | Imidazopyridine compounds useful in the treatment of ulcers | |
JP2002531501A (en) | GLP-1 receptor non-peptide antagonists and methods of use | |
JPH02218682A (en) | Ergorine derivative | |
EP0315112B1 (en) | Novel amide compounds | |
JP2005239611A (en) | Pyrazolopyrimidine derivative and its application | |
CN101166729B (en) | Fused heterocyclic compounds | |
JPH01211580A (en) | Substituted imidazole derivative | |
US4720496A (en) | Pyridotriazoloquinazolines and triazolopyridoquinazolines useful as antiallergics | |
US5336679A (en) | Tetrahydroimidazopyridine derivatives and salts thereof | |
JPH10505330A (en) | Halogen imidazopyridine | |
JPH05112559A (en) | 4-amino-5-pyrimidinecarboxylic acid derivative | |
JPH05331149A (en) | Phenol derivative | |
JPH0269477A (en) | Substituted imidazole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004810065 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2543707 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007135452 Country of ref document: US Ref document number: 2006538217 Country of ref document: JP Ref document number: 10577334 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004810065 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10577334 Country of ref document: US |